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Abstract
Permanent breast seed implantation (PBSI) is a promising breast radiotherapy tech-
nique that suﬀers from operator dependence. We propose and have developed an intra-
operative 3D ultrasound (US) guidance system for PBSI.
A tracking arm mounted to a 3D US scanner registers a needle template to the
image. Images were validated for linear and volumetric accuracy, and image quality
in a volunteer. The tracking arm was calibrated, and the 3D image registered to the
scanner. Tracked and imaged needle positions were compared to assess accuracy and a
patient-specific phantom procedure guided with the system.
Median/mean linear and volumetric error was ±1.1% and ±4.1%, respectively, with
clinically suitable volunteer scans. Mean tracking arm error was 0.43mm and 3D US
target registration error ≤0.87mm. Mean needle tip/trajectory error was 2.46mm/1.55°.
Modelled mean phantom procedure seed displacement was 2.50mm. To our knowledge,
this is the first reported PBSI phantom procedure with intraoperative 3D image guidance.
Keywords: Ultrasound, 3D Ultrasound, Image Guidance, Brachytherapy, Radiation
Therapy, Breast Cancer
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Chapter 1
Introduction
1.1 Early Stage Breast Cancer and its Treatment
1.1.1 Breast Cancer and its Progression
For Canadian women, breast cancer is the most commonly diagnosed cancer and the
second highest cause of cancer related death, with an estimated 26,300 new cases and
5,000 deaths in 2017 [1]. Globally, breast cancer is the 2nd most common cancer and
the 5th highest cause of cancer death, with an estimated 1.7 million cases and 522,000
deaths in 2012 [2].
Like all cancers, if left untreated breast cancer follows a progression from a localized
group of abnormal cells to larger invasive tumours that spread (metastasize) to other
parts of the body via the lymph nodes and circulatory system. The extent of progression
is categorized by stage from 0–4, as summarized in Figure 1.1. Assessment of cancer
stage acts as a strong indicator of prognosis, influencing the choice of treatment for each
patient.
Cancer stages are defined using the Tumour-Node-Metastasis (TNM) system, which
provides criteria to score the cancer’s progression with respect to the size of the original
tumour, any spread to nearby lymph nodes, and the presence or absence of distant
metastases. Each item on the TNM scale is given a numeric rating (T:0-4,N:0-3, M:0-1),
sometimes with additional sub-specification (e.g. Tis for carcinoma in situ), and the
aggregation of the three scores is used to define the cancer stage. A simplified version
of the definition of cancer stage by TNM category is shown in Table 1.1. The term
“early-stage” breast cancer generally refers to stages 0–2 [4].
While knowledge of cancer stage is useful for prognosis and treatment selection, the
definition of stage is primarily anatomic, despite a growing number of non-anatomic
biomarkers [6]. Of those non-anatomic biomarkers, three are routinely assessed clinically
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Figure 1.1: Summary of the stages of cancer progression. Adapted from Canadian Part-
nership Against Cancer, 2015 [3]
Table 1.1: Simplified table of stage by TNM classification. Adapted from American
Joint Committee on Cancer, 2009 [5]. Note that stages appear to overlap in individual
categories (T/N/M) only because stage is dependent on all categories (e.g. T2N1M0
is stage 1 while T2N2M0 is stage 2). Tis = tumour - carcinoma in situ; N1mi = N1
micromestasis)
Stage T N M
Stage 0 Tis N0 M0
Stage I T0-1 N0-1mi M0
Stage II T0-3 N0-1 M0
Stage III T0-4 N0-2 M0
Stage IV Any T Any N M1
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in breast cancer: the expression of two hormone receptors, estrogen receptor-α (ER) and
progresterone receptor (PgR), and the presence of HER2 (human epidermal growth factor
receptor 2) [7]. All three of these biomarkers indicate a variable by which the cancer cells
can be diﬀerentiated from healthy cells, making it possible to supplement treatment with
targeted therapies. ER and PgR status, referred to as ER or PgR positive respectively,
are indicative of tumour cells whose growth is dependent on estrogen, making it possible
to target these cells using drugs that either disrupt the interaction of estrogen with
these receptors, selective estrogen receptor modulators (SERMs) such as tamoxifen, or
that suppress the production of estrogen, such as aromatase inhibitors. Approximately
75% of invasive breast cancers are ER positive and 60–70% are PgR positive [7], with
hormone receptor (HR) positive tumours having a generally favorable prognosis relative
to HR negative tumours [8]. The third biomarker, HER2, is a proto-oncogene (precursor
to a gene that can cause cancer) that is amplified in 20–30% of invasive breast cancers
[9]. HER2 positive tumours can be targeted with an antibody based treatment called
trastuzumab (trade name Herceptin), which is considered an integral part of therapy for
patients with HER2 positive tumours [9].
In addition to tumour specific biomarkers, genetic risk factors for breast cancer have
also been identified, most notably mutations in the BRCA1 and BRCA2 genes. These
genes are both involved in a key pathway for the repair of DNA damage (homologous
recombination repair) and cells with mutations in these genes must rely on a secondary
pathway (non-homologous end joining) that is more error-prone [10]. The reliance on an
error-prone repair pathway leads to more frequent mutation and a greater risk of tumour
development, with an estimated lifetime breast cancer risk of >80% [11]. Despite the
exceedingly high breast cancer incidence amongst women with BRCA1/2 mutations,
evidence on their value as a prognostic indicator remains unclear [12].
1.1.2 Treatment of Early Stage Breast Cancer
Techniques for breast cancer treatment can be summarized into three categories:
surgical, systemic, and radiation therapies.
With respect to surgical therapies, one well-established treatment for early stage
breast cancer is breast conserving surgery (BCS), also known as lumpectomy, in which
the primary tumour is surgically removed while sparing the remainder of the breast.
When followed by adjuvant whole breast irradiation (WBI), the combined treatment
regimen is referred to as breast conserving therapy (BCT) and is considered the standard
of care for early stage breast cancer [13]. Following the surgery, the removed tissue is
analyzed histologically to provide additional information about the tumour type and to
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examine the extent of normal tissue clearance around the excised tumour. The extent
of normal tissue around the excised tumour, is referred to as the excision ‘margins’.
‘Positive margins’ indicate that the tumour comes to the edge of the excised volume, likely
indicating that not all of the tumour was removed, making it an indication for re-excision
[14]. An excised tumour may also be considered to have ‘close margins’ if the amount
of normal tissue around the tumour is less than a prespecified safety margin, typically
on the order of 1–5mm [14]. While close margins may indicate further treatment, such
as re-excision, consensus guidelines published in 2013 indicate that more widely clear
margins do no decrease the rate of ipsilateral recurrence [14].
Breast conserving therapy was introduced as an alternative to mastectomy [15], or
the surgical removal of the entire aﬀected breast, in order to achieve a better cosmetic
outcome while still addressing the disease. Although the eﬀectiveness of BCT has been
established, mastectomy is still necessary for certain patients such as those with multi-
centric disease (i.e. multiple tumours in the same breast), patients for whom a lumpec-
tomy has failed to achieve negative margins, or for locally recurrent cases [16].
Systemic therapies refer to treatments that travel through the blood stream, reaching
cells throughout the body. While early-stage cancers are, by definition, localized to the
breast, it is generally accepted that a portion of patients with disease that is localized by
clinical standards will have micro-metastases that are not presently detectable. The risk
of micro-metastases motivates the exploration of systemic therapies in combination with
surgical and/or radiotherapeutic treatments, even for early-stage disease [17]. Cytotoxic
chemotherapy is one form of systemic therapy which uses drugs that preferentially target
rapidly dividing cells, typically administered in a combination therapy of multiple drugs
[18]. A review of international guidelines suggested that chemotherapy is indicated for
patients with tumours >1 cm or with nodal involvement [19].
In addition to the traditional chemotherapeutic forms of systemic therapy, targeted
therapies for the cancer subtypes discussed in section 1.1.1 above, namely SERMS or
aromatase inhibitors for ER and/or PgR positive tumours and trastuzumab for HER2
positive tumours, are typically indicated when the appropriate subtype has been identi-
fied.
Lastly, radiotherapy is an important component of breast cancer management, with
the radiobiology and delivery techniques of radiotherapy discussed in more detail below.
Often radiotherapy is used in conjunction with surgery, as in BCT, with the intention
of killing any occult, microscopic deposits of cancerous cells that would be missed by
typical resection margins [20].
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1.1.3 Breast Radiotherapy
The delivery of breast radiotherapy may use one of two classes of techniques: ex-
ternal beam radiotherapy (EBRT) and brachytherapy, with EBRT currently being by far
the most common. In EBRT, a linear particle accelerator (linac) is used to generate a
beam of ionizing radiation that is directed towards the patient. The beam is shaped or
modulated using secondary collimation such as jaws or multi-leaf collimators (MLC’s)
in combination with step-and-shoot or arc delivery techniques [21]. EBRT may deliver
photons or electrons, depending on the device used to produce them and its configuration,
with energies typically ranging from 4–20MeV [21].
Conversely, brachytherapy uses a sealed source, such as a radioactive seed or wire,
placed in or near the target, such as inside a tumour or at the surface of a superficial lesion.
The prefix ‘brachy’ comes from the Greek word for ‘short’, reflecting the short distance
between the source and the target. The “sealed” source of brachytherapy contrasts with
the use of systemic radiotherapy, in which radioactive compounds enter the bloodstream,
such as orally administered iodine-131 to treat thyroid cancer [22].
Brachytherapy may be further categorized by the rate at which dose is delivered.
Low, medium, and high dose rate (LDR, MDR, and HDR, respectively) brachytherapy
is defined as dose rates from 0.2–0.4Gy/h, 2–12Gy/h and >12Gy/h, respectively [23].
Brachytherapy radiation may also be delivered intermittently, known as pulsed dose rate
[23], although in modern practice LDR and HDR brachytherapy are most common.
While LDR brachytherapy can be delivered by manually placing sources, HDR bra-
chytherapy is potentially dangerous to the operator and is delivered automatically and
remotely using a device called an afterloader. An afterloader is an electronic device that
uses motors and sensors to sequentially move a single radioactive source attached to the
end of a wire through multiple catheters implanted in or placed near the target. The
dose is adjusted based on where the source is moved (dwell positions) and how long it
stays there (dwell times). Dwell times and positions are specified in a treatment plan
determined based on target geometry determined from imaging of the area [24]. Treat-
ment times are in the range of minutes, and are delivered in discrete ‘fractions’, similar
to the EBRT approach. Energies of commonly used brachytherapy sources range from
21–1250 keV [23].
1.1.4 Radiobiology
Ionizing radiation disrupts cells by damaging deoxyribonucleic acid (DNA), a large
molecule who’s structure is characterized by its famous double-helix shape [10]. The
energy deposited by ionizing radiation can damage the structure of DNA by breaking
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one or both strands of the double-helix, known as single- and double-stranded breaks,
respectively. Double stranded breaks are thought to be the most important DNA lesions
for radiotherapy as they are principally responsible for cell killing [10]. While ionizing
radiation causes damage to healthy cells, it is especially damaging to cancerous cells
[25], creating a diﬀerential response that allows radiation to be used for treatment. The
magnitude of the diﬀerence in response between cancerous and non-cancerous cells can be
described in terms of the therapeutic ratio, also known as the therapeutic index, which is
defined as the ratio of the tumour control probability to the normal-tissue complication
probability for a fixed level of normal tissue damage [10].
As a result of the eﬀect of ionizing radiation on both cancerous and healthy cells,
radiotherapy is often accompanied by adverse events. These side-eﬀects are caused by
either radiation damage to the surrounding healthy tissue of the target organ or to other
nearby organs, termed organs-at-risk (OARs). In the case of breast radiotherapy, OARs
include the heart, lungs, skin, ribs and contralateral breast [26]. Adverse events of the
skin can include erythema (redness), moist desquamation, telangiectasia, and induration
[27], while other organ adverse events include cardiomyopathy and secondary cancers
[28].
The biological eﬀects of radiotherapy are characterized principally by the dose de-
livered to tissues measured in Gray (Gy), where 1Gy corresponds to 1 joule of absorbed
energy from ionizing radiation per kilogram of matter [29]. The dose delivered during
radiotherapy is calculated using simulations based on the geometry of the target (e.g.
tumour) relative to the source, and established calibration data describing the dose dis-
tribution. In the case of EBRT, the dose distribution is a function of penetration depth,
and in the case of brachytherapy it is a function of distance and angle from the source.
The attenuation of dose as it travels through a medium (e.g. tissue) depends on the
beam characteristics, with lower energy photons attenuated more rapidly, but generally
reach a maximum at or near the entry point of the beam, for EBRT, or adjacent to the
source, for brachytherapy, and decay to zero with increasing depth.
In addition to the dose delivered to tissue, biological eﬀects are also strongly influ-
enced by the timing in which the dose is received. Radiotherapy is usually separated into
a series of small treatments separated by hours or days, referred to as fractionation, to
best leverage the radiobiological phenomena related to cell death. These phenomena are
often summarized by the “five R’s of radiobiology”: reassortment, repopulation, reoxy-
genation, repair, and radiosensitivity [10, 30]. Reassortment refers to the redistribution
of cells amongst the various stages of the mitotic cell cycle. Cells are more susceptible
to radiation damage in some stages than others due to diﬀerences in the dominant DNA
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repair mechanisms, making reassortment a mechanism of sensitizing cells that might have
been radioresistant during a previous fraction. Repopulation refers to the regrowth of cell
populations, healthy or cancerous, to replace cells killed by radiation therapy. Reoxygen-
ation refers to the return of oxygen supply to tumour cells to maximize its radiosensitizing
eﬀects in catalyzing the permanent damage of DNA by free radicals. Repair refers to the
ability of cells to repair sublethal damage to their DNA. Lastly, radiosensitivity refers to
intrinsic diﬀerences in the radiosensitivity of diﬀerent cell types. The historical rationale
for fractionated therapy is that it leverages the repair and repopulation of healthy cells
to minimize toxicity, while allowing reoxygenation and reassortment to radiosensitize
cancerous cells [10].
The relationship between the dose of the fraction delivered and its eﬀect on cell
killing has been studied extensively, resulting in the linear-quadratic (LQ) model. In the
LQ model, the eﬀect of radiation damage on cell survival is modelled as the sum of two
components, one linear with respect to dose (α), and the other quadratic (β), summarized
in equation 1.1:
S = eαD+βD
2
(1.1)
where S is the surviving fraction of cells, D is the radiation dose and α and β are constants
representing properties of a given tissue type. In this model, the linear component is
thought to represent the eﬀect of directly lethal damage to the cells while the quadratic
component is though to represent cell–death due to accumulation of sub-lethal damage.
The LQ model allows for dosage in diﬀerent fractionation schemes to be calculated such
that they result in the same survival fraction, a concept referred to as biologically eﬀective
dose (BED) [10]. As a result, prescribed dose in a regimen with greater fractionation
tends to be higher in order to achieve the same BED.
Additionally, BED is dependent on the values of α and β, specifically on the ratio
of α/β, which vary with diﬀerent tissues. Cancerous tissue tends to have a higher value
of α/β than late responding normal tissue, such that the reduction in BED due to frac-
tionation is greater for healthy tissues than cancerous tissues. As a result, fractionation
generally allows for the therapeutic ratio to be increased by raising the BED delivered
to cancerous tissue while keeping the BED of late responding healthy tissues constant.
Traditionally the values of α/β used in BED calculations were taken as 3Gy for late
responding normal tissues and 10Gy for cancerous tissues [31].
Conceptually, the continuous radiation delivery of permanent seed brachytherapy
may be viewed as a special case of fractionation in which treatment is given in an infinite
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number of fractions separated by an infinitely small period of time. However, application
of the usual equations for BED to permanent seed brachytherapy is complicated by the
decaying dose rate over time and by the violation of the usual assumption that time
between fractions is sufficient for all sub-lethal radiation damage to be repaired.
While traditional calculations for BED have used the values of 3Gy and 10Gy to
represent α/β of all cancerous and late responding normal tissues, respectively, recent
research has explored breast cancer specific values of α/β. Analysis of data from a phase
III randomized clinical trial comparing diﬀerent fractionation schedules of whole breast
irradiation following lumpectomy showed that the diﬀerence in α/β between healthy and
cancerous tissue in this context may be much smaller than previously thought. Estimated
α/β for local-regional relapse was 4.6Gy (95% CI 1.1–8.1Gy) and for changes in breast
appearance was 3.4Gy (95% CI 2.3–4.5Gy) [32]. This evidence suggests that the dif-
ference in α/β between cancerous and healthy tissue in breast cancer may be smaller
than previously thought, or possibly even reversed. A relatively low value of α/β in
breast cancer would support the use of hypofractionation, although the available data is
not yet conclusive. Despite the clear implications of α/β for fractionated radiotherapy,
radiobiological models for comparing fractionated regimens to continuous, low dose rate
radiotherapy (i.e. permanent seed brachytherapy) depend on the recovery rate of sub-
lethal damage but are relatively independent of α/β [33]. Thus, the implications of the
emerging research on α/β of cancerous and healthy breast tissue for permanent seed
breast brachytherapy (discussed below) are unclear.
1.2 Accelerated Partial Breast Irradiation
1.2.1 Rationale and Key Concepts
In the years of clinical follow-up on the treatment of early-stage breast cancer with
BCT, a pattern was observed in which recurrences were more likely to occur at the site of
the originally treated tumour [13]. Research investigating the addition of a targeted boost
of radiation to the tumour bed in addition to WBI showed improvements in ipsilateral
recurrence [34], supporting targeted irradiation as a strategy to improve therapy.
If increased dose to high-risk regions could improve eﬀectiveness, could reduced dose
to low-risk regions reduce treatment burden? Such was the motivation for accelerated
partial breast irradiation (APBI), the delivery of radiation to only a portion of the breast
surrounding the original tumour site at an accelerated rate.
In the context of traditional WBI, the treatment burden is considerable, requiring
frequent trips to the hospital over many weeks. Traditional radiation schedules separated
treatment into 25 fractions of 2Gy each [35] (50Gy total), typically delivered once a day,
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five days a week for five weeks. The addition of a targeted boost can extend the total
treatment time to 6–7 weeks [34]. While more recent clinical trials have shown equivalent
tumour control when whole breast irradiation is shortened to 40Gy over 15 fractions
(2.67Gy each) [35], this 3–week radiation schedule remains burdensome.
The treatment burden is hypothesized to cause some women to choose mastectomy
instead of BCT or even decline radiotherapy and accept an increased risk of recurrence,
with evidence for that hypothesis reflected in both anecdotal [36] and statistical accounts
[13]. Anecdotally, there is the account of a Venezuelan woman treated using interstitial
brachytherapy at the Oschner Clinic in New Orleans, USA, the first APBI patient in
the modern era, for whom there were no linear accelerators in her home country within
8 hours of her home [36]. Statistically, BCT is often underutilized, with the proportion
of eligible patients who undergo BCT estimated between 35–80% and the proportion
of patients who receive BCS but forego radiation therapy estimated between 15–30%
[13]. The lengthy duration of radiation treatment is widely thought to contribute to this
underutilization [37]. Additionally, several factors that increase the burden of an extended
treatment; including distance to treatment, ambulatory status and rural populations;
correlate with underutilization of BCT [13]. As a result, APBI is hypothesized to of-
fer a tool to increase the utilization of BCT by eligible patients in addition to reducing
the treatment burden of those who would have received radiation therapy regardless of
treatment length.
Writing against this hypothesis, Yao & Recht [38] found that the increased use of
APBI brachytherapy amongst breast cancer patients in the United States from 0.2–3.1%
between 2000–2008 did not correspond to a reduction in the proportion of patients who
did not receive radiotherapy. They conclude that the removal of “institutional, logistical
and financial barriers” may be more promising avenues to reduce noncompliance [38].
Despite having data from over 300,000 patients, the authors lack data on the proportion
of patients for whom APBI brachytherapy was available or their characteristics, nor on
any control group that might account for other influences on treatment patterns. As a
result, their attribution of a lack of reduction in non-compliance to a failed promise of
APBI brachytherapy is largely without evidence.
The observation of the local nature of tumour control and recurrence as well as the
significance of treatment burden on breast cancer patients, led to the rise of accelerated
partial breast irradiation (APBI) as an active area of research. It was hypothesized
that APBI could maintain tumour control with rates of adverse eﬀects held constant or
improved while accelerating the treatment and reducing the burden to the patient.
In planning and delivering APBI, target volumes are defined based on terminology
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consistent with radiation therapy planning more broadly. In radiotherapy planning, gross
tumour volume (GTV) refers to any visible tumour volume under imaging or clinical
exam, while the clinical target volume (CTV) includes the GTV as well as subclinical
disease not visible under imaging. The CTV thus defines the volume of tissue that
is clinically relevant for treatment. The planning target volume (PTV) represents an
expansion to the CTV to account for any inaccuracies in set-up or delivery [39]. In
the context of APBI more specifically, treatment is generally delivered to the surgical
cavity (seroma) following lumpectomy rather than to the tumour itself. Thus, GTV is
not generally defined, while borders of the CTV and PTV are determined by expanding
contours of the seroma; the fluid-filled cavity left behind from surgery.
1.2.2 Eligibility and Clinical Evidence
With the primary motivations for using APBI over WBI related to improving second-
ary treatment considerations, such as adverse eﬀects and treatment burden, rather than
the primary consideration of tumour control, inclusion criteria are limited to patients
for whom tumour control from established therapy is already very good. Task groups
representing national or international bodies have published recommendations for APBI
eligibility criteria, including the American Brachytherapy Society [40], the American So-
ciety for Radiation Oncology [41], the American Society of Breast Surgeons [42], and
the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and
Oncology (GEC-ESTRO) [43]. Additionally, many large-scale clinical trials (discussed
below) have defined their own criteria. Despite variation between recommendations, most
contain a minimum age (>45–60), a maximum tumour size (<2–3 cm), tumour margin
requirements (negative margin >0–2mm) and little to no lymph-node involvement (≤0–3
nodes). Eligibility recommendations of the task groups mentioned above are summarized
by Tann et al. [44] and those used by various phase III clinical trials are described in the
citations and clinical trial registry numbers given in Table 1.2.
The most robust source of evidence for the clinical efficacy of APBI is derived from
five phase III randomized clinical trials (RCTs) comparing ipsilateral breast tumour re-
currence following APBI and WBI. The results of these studies and the techniques of
APBI they evaluated are given in Table 1.2, alongside descriptions of four ongoing phase
III RCTs and their expected study completion dates (ESCD). Five–year recurrence rates
in the control arms of the phase III RCTs published to date have all been ≤1.5%, il-
lustrating the favorable prognosis of eligible patients. In the treatment arms, three of
the five studies (GEC-ESTRO, Florence [NCT02104895], and IMPORT-LOW) have un-
ambiguously promising results, with 5–year recurrence rates also ≤1.5%, none of which
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were statistically significantly diﬀerent from their control arms. Of the remaining two
trials, ELIOT and TARGIT-A, both were delivered with intraoperative radiotherapy
(IORT). Recurrence rates in the ELIOT trial were worse than the treatment arm (4.4%
vs 0.4%, p<0.0001) while diﬀerences in recurrence rates of the TARGIT-A trial (3.3%
treatment vs 1.3% control) had a p-value of 0.04. However, recurrence rate diﬀerences
in TARGIT-A were deemed not significantly diﬀerent by the study’s authors due to a
pre-defined significance level of 0.01 to reflect multiple comparisons [45]. The study’s au-
thors concluded the results demonstrated non-inferiority, although interpretation of the
trial was met with considerable controversy when it was published (discussed in section
1.2.5 below).
Two recent reviews of the clinical efficacy of APBI reached contradictory conclusions,
with one excluding IORT trials and concluding that the efficacy of APBI relative to WBI
was supported [46], while the other included IORT trials and concluding the opposite
[47]. Both reviews were written prior to the publication of the IMPORT-LOW trial,
which provided additional evidence supporting APBI.
In summary, with the possible exception of IORT based approaches, data available
from multiple large RCT’s supports the use of APBI for well-selected patients, with
results from other RCT’s comprising an additional 10,000 patients pending in the coming
years.
1.2.3 Interstitial and Intracavitary Breast Brachytherapy
The first modern treatment of APBI was delivered using interstitial breast brachy-
therapy [36], in which 15–25 needles are inserted into the breast and exchanged for
flexible catheters [54]. With the catheters implanted, an afterloader is used to deliver
HDR brachytherapy over the following week based on a treatment plan developed using
CT. Treatment is typically fractionated over five days, after which the catheters are
removed. LDR brachytherapy has been delivered using iodine-125 (125I) or iridium-192
(192I) but the most common source configuration is HDR 192I [55].
Despite initial success with interstitial brachytherapy, the technique was not widely
adopted. Planning and delivering the procedure is time-consuming and requires a spe-
cialized skill set [37], and with limited availability of adequate training, adoption was
largely limited to high-volume centres [13].
As a result, the intracavitary approach was developed to simplify breast brachyther-
apy, placing an instrument into the seroma through an incision where it expands to fill
the cavity and is left in place. Like the interstitial approach, a remote afterloader is
used to deliver a source through one or more lumens within the implanted device. The
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Table 1.2: Summary of completed and ongoing phase III prospective randomized clinical
trials comparing APBI to WBI. Adapted from Tann et al. 2016 [44] with the addition of
recently published results from Coles et al. 2017 [48] on the IMPORT-LOW trial.
Trial # of
Patients in
Trial
Follow-up
Period
(Years)
APBI
Technique
5–Year LR,
APBI vs
WBI
TARGIT-A [49] 3451 2.4 IORT 3.3 vs 1.3
ELIOT [50] 1305 5.8 IORT 4.4 vs 0.4
GEC-ESTRO [51] 1184 5.0 MIB 1.4 vs 0.9
Florence
(NCT02104895) [52]
520 5.0 EBRT (IMRT) 1.5 vs 1.5
IMPORT-LOW [48] 2018 6.0 EBRT (IMRT) 0.5 vs 1.5
IRMA
(NCT01803958)
3302 Pending EBRT
(3D-CRT)
Pending
(ESCD: Apr
2020)
NSABP B-39/ RTOG
0413 (NCT00103181)
4300 Pending MIB or ICB or
EBRT(3D-
CRT)
Pending
(ESCD: Apr
2020)
RAPID (OCOG) [53]
(NCT00282035)
2135 Pending EBRT(3D-
CRT)
Pending
(ESCD: Dec
2020)
SHARE
(NCT01247233)
1006 Pending EBRT(3D-
CRT)
Pending
(ESCD: Oct
2025)
3D-CRT: 3D conformal external-beam radiotherapy; ESCD: estimated study completion date (from clin-
icaltrials.gov as of Sep 2017), ICB: intracavitary brachytherapy, LR: local recurrence, MIB: multicatheter
interstitial brachytherapy, IMRT: intensity modulated radiotherapy, IORT: intraoperative radiotherapy
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first intracavitary device developed was the MammoSite applicator, approved by the
FDA in 2002 [13], which contained a single centrally positioned lumen inside of a spher-
ical balloon. The symmetrically shaped applicator and single lumen mean the device
is unable to deliver asymmetrical dose distributions and adequate conformance to the
seroma may be problematic [13]. Newer, multi-lumen devices such as the MammoSite
ML (multi-lumen) and the Contura balloon applicator, as well as the non-balloon based
strut adjusted volume implant (SAVI) device, have since been developed to oﬀer greater
dosimetric flexibility, including the delivery of asymmetrical plans. As of 2017, Hologic,
the makers of MammoSite ML and the Contura device, claim that over 90,000 women in
the United States have received intracavitary APBI using their devices [56].
1.2.4 External Beam APBI
In addition to brachytherapy approaches to APBI, several techniques also exist us-
ing EBRT, principally 3D conformal radiotherapy (3D CRT) and intensity-modulated
radiotherapy (IMRT). In 3D CRT, MLCs are used to modify the shape of the beams to
conform to the outline of the PTV in the ‘beams-eye view,’ reducing the dose delivered
to healthy tissue. Conversely, IMRT modifies both the shape and intensity of the beams,
using the motion of the MLC leaves to modify the dose across the beam by leaving some
portions of the field open for more time than others.
In completed and ongoing phase III clinical trials of APBI that incorporated an
external beam arm, dose fractionation schemes range from 30–40Gy to the PTV in 5–15
fractions [44]. The most common fractionation scheme, used in the three largest phase III
clinical trials of EBRT, is 38.5Gy in 10 fractions delivered over 5–10 days. A simulation-
based dosimetric analysis of organs at risk during APBI suggested that EBRT-APBI
techniques deliver less dose to OARs than WBI or MIB [28].
1.2.5 Intraoperative Radiotherapy
Intraoperative radiotherapy (IORT), a form of brachytherapy, uses a mobile, elec-
tronic device implanted in the surgical cavity during the lumpectomy. Depending on the
device, radiation may be delivered in the form of photons in the 30–50 keV range, or
as electrons in the 3–12MeV range [13]. By delivering radiotherapy concurrently with
lumpectomy, radiotherapy is delivered without any additional treatment visits, making
this approach the most convenient and timely option for patients. However, as was noted
above, positive margins are typically an exclusion criterion for APBI and this inform-
ation is not available at the time of lumpectomy. To address this, some studies have
adopted a “risk-adapted” approach in which patients with adverse features identified
post-lumpectomy were given standard WBI, a criterion aﬀecting approximately 15% of
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patients, with IORT serving as a radiation boost to the tumour bed [45].
There are two published phase III RCT’s incorporating IORT, the ELIOT trial and
the TARGIT-A trial, both of which are discussed in Table 1.2. ELIOT compared electron
based IORT to WBI in an equivalence design and found that electron based IORT had
significantly higher rates of recurrence (4.4% vs 0.4%, hazard ratio 9.3) [50]. Despite
these rates being within a prespecified equivalence margin (7.5%) [50], the results were
viewed as disappointing [57] and the increased recurrence attributed to patient selection
[50, 57].
Conversely, TARGIT-A used photon based IORT and stratified sampling into pre- and
post- histology groups. The pre-histology group was randomized prior to lumpectomy
and used the risk-adapted approach described above, while the post-histology group was
randomized after histology was available and IORT performed by reopening the surgical
cavity. The TARGIT-A trial found 5–year local recurrence rates for TARGIT and EBRT
of 3.3% and 1.3%, respectively (p = 0.04), considered not statistically significant due to
a pre-specified significance level of 0.01 to account for repeated tests due to an interim
analysis published in 2010 [58]. The authors concluded that recurrence was within a
pre-specified non-inferiority margin of 2.5% [49].
Publication of the results from the TARGIT-A trial were met with considerable
controversy, with at least six commenting articles critical of the trial published in re-
sponse [35, 57, 59–62]. Criticisms focus on a relatively short follow-up (median 2 years,
5 months), concerns around the statistical design and interpretation of a non-inferiority
trial, and whether a decrease in non-breast-cancer related deaths is attributable to re-
duced radiation exposure. Despite IORT oﬀering the potential for the shortest, most
convenient treatment option, interpretation of the clinical evidence to date remains mired
in controversy.
1.2.6 Emerging Techniques in APBI
In addition to the techniques described above, other emerging forms of APBI have
also been described in the literature including non-invasive breast brachytherapy (NIBB)
and ablative radiotherapy.
NIBB is delivered using the AccuBoost Brachytherapy System (Advanced Radiation
Therapy, Inc., Billerica, MA). The system uses mammography-like compression paddles
with on-board kV x-ray imaging to image the breast and deliver brachytherapy using
applicators positioned on the opposite side of the paddles. An HDR 192Ir source is
delivered to the applicators using an afterloader and the process repeated at both a
medial-lateral and cranial-caudal orientation of the paddles [63]. Although the device
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has been used for standalone APBI, clinical trials of this application of the device have
so far been limited to assessment of 40 patients to evaluate feasibility and tolerability
[63].
There are also emerging EBRT techniques for APBI, including stereotactic body ra-
diation therapy (SBRT) and preoperative radiation therapy [64]. SBRT, also known as
stereotactic ablative radiotherapy (SABR) [65], delivers radiotherapy in very large frac-
tions, generally 10–20Gy per fraction over 1–5 fractions [66]. Conversely, preoperative
radiotherapy is a form of APBI that delivers radiotherapy pre-lumpectomy rather than
post-lumpectomy, as is customary amongst more established APBI methods [64]. SBRT
and preoperative radiotherapy are not mutually exclusive, with some SBRT trials deliv-
ering radiation preoperatively [64]. As of this writing, there are at least six ongoing trials
of SBRT APBI as well as five ongoing trials of non-stereotactic, preoperative APBI [64].
1.2.7 Permanent Breast Seed Implantation
Pioneered at Toronto’s Sunnybrook Hospital, Permanent Breast Seed Implantation
(PBSI) uses permanently implanted seeds of palladium-103 (103Pd) to deliver radiation
therapy. Once the seeds are implanted, the patient is sent home while the seeds decay over
the course of approximately two and a half months (half-life 17 days). Once decayed, the
seeds are biologically inert and can safely remain in the patient. The use of permanently
implanted seeds to deliver brachytherapy is used most widely in prostate brachytherapy,
where seeds of 125I are implanted via needles inserted through the perineum [67]. PBSI
uses the same principles as the prostate procedure [68], using the lower energy 103Pd
seeds rather than 125I (average of 21 keV vs 27MeV) in order to keep the radiation dose
to others (e.g. patient’s partner/spouse) within safe levels [69, 70].
Currently, PBSI is planned and delivered according to the methods first described by
Pignol et al. [68] and later modified by Batchelar et al [71]. A radiation treatment plan
is crafted using a planning X-ray computed tomography (CT) scan with intraoperative
image guidance provided by 2D ultrasound (US). The seroma and surrounding fibrosis
is contoured in the CT scan and expanded by 10mm, cropped to a minimum distance of
5mm from the skin and chest wall, to define the CTV [27]. The PTV is an additional
5mm expansion (15mm total) that is also cropped 5mm from the skin and chest wall
[27]. Prescribed does to the PTV is 90Gy, with plans calling for (mean ± SD) 75 ± 18
seeds delivered using 17 ± 4 needles [72].
Delivery of the treatment plan is then implemented intraoperatively using a standard
needle template, felt markings outlining a projection of the PTV onto the skin surface,
and intraoperative 2D US [71]. The needle template consists of a rectangular plate with
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a regular grid of holes through which needles are inserted. The template is oriented such
that needle trajectory is approximately tangential to the chest wall to minimize the risk
of chest wall perforation. A ‘fiducial needle’ is inserted through the centre of the seroma
in order to provide, in combination with the template, a reference for how far needles
have been inserted [73]. With the fiducial needle inserted, the seed-bearing needles are
inserted according to the dosimetric plan. Observed diﬀerences in seroma shape from
the planning CT are noted by the clinician and any changes to the treatment plan made
manually [71].
Clinical outcomes of a combined cohort of 134 patients are available with a median
follow-up of 63 months [27]. Five-year local recurrence-free survival for the cohort was
98.8 ± 1.20%, similar to estimates for the cohort based on established statistical tables
(nomograms) of 98.5 ± 0.98% (p = not significant) [27]. Rates of radiation-related
side-eﬀects were similar to that of whole breast irradiation [27].
In addition to clinical eﬀectiveness of the procedure, a recently published study of
cost-eﬀectiveness found that the average societal cost (sum of costs to the healthcare
system and patient) of treating a patient with PBSI is only modestly more than the cost
of traditional 25–fraction WBI, $8700 CAD vs $6200 CAD [74]. Subsequent analysis of
the paper’s findings, published as a letter to the editor in response to the study [75],
showed their model predicts a ‘threshold distance’ of 94 km for one-way travel, above
which the societal cost of PBSI is lower than WBI due to increasing patient travel costs.
The letter further argues that, due to the model’s assumptions, the true threshold is likely
lower [75]. The text of this letter and accompanying analysis are included in this thesis
as Appendix A. Subsequent response from the study’s authors confirmed the modelled
threshold and agreed with the hypothesis that the true threshold is likely lower [76].
To illustrate the significance of this threshold in the Canadian context, Figure 1.2
shows the resulting travel distance boundary around 46 Canadian radiation oncology
centres. Based on our analyses and on the cancer centres identified, for Canadian patients
living outside of the areas highlighted in red, PBSI is a more cost-eﬀective option than 25-
fraction WBI. We estimate that the areas for which PBSI is more cost-eﬀective represent
approximately 15% of the Canadian population.
Centres were identified based on directories of the Canadian Association of Radiation
Oncologists and the Canadian Organization of Medical Physicists. Population estimates
were made based on data from the Gridded Population of the World, version 4 as pub-
lished by the United States National Aeronautics and Space Administration (NASA). A
detailed description of the methods used to create the map and estimate the correspond-
ing population, as well as a list of the radiation oncology centres identified are included
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Figure 1.2: Illustration of the geographic areas of Canada within 93.6 km travel distance of
a Canadian Cancer Centre. For Canadian patients living outside of the areas highlighted
in red (estimated 15% of the Canadian population), our analysis revealed that PBSI is
less costly than standard radiotherapy. Available online as an interactive map: http:
//bit.ly/94kmMap
in this thesis as Appendix B.
Highlighted areas are based on travel distance by car as estimated by Google Maps
(Google Inc., Menlo Park, USA). Cities located outside the travel distance isoline include:
Kamloops, BC (Pop. 90,000); Medicine Hat, AB (Pop. 63,000); Fort McMurray, AB (Pop.
61,000); Sault Ste Marie, ON (Pop. 73,000); North Bay, ON (Pop. 52,000); Sarnia, ON
(Pop. 72,000); and Fredericton, NB (Pop. 58,000).
An additional study of PBSI is currently ongoing and recruiting participants [77].
Although inclusion/exclusion criteria have varied slightly for past studies of PBSI, sum-
marized by Pignol et al. [27], the criteria used in the ongoing trial accepts patients ≥55
years of age with unifocal stage 0–1 breast cancer, a tumour ≤ 2 cm in size that is ER
positive, clear surgical margins and without known genetic mutation in BRCA1/2 [77].
In addition to the aforementioned criteria, generally consistent with criteria for APBI in
general, technical constraints of PBSI also require a seroma ≤3 cm in diameter that is
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clearly visible in US and CT and that results in a PTV of ≤125 cm3.
PBSI oﬀers a promising technique for the delivery of APBI, decoupling the rela-
tionship between patient burden and duration of radiotherapy to achieve a convenient,
single-visit therapy while maximizing the radiobiological benefits of prolonged radiation
to deliver promising recurrence rates in phase I/II clinical trials.
1.3 Challenges of PBSI
1.3.1 Operator Dependence and Previous Work
PBSI is a technically demanding procedure and operator dependence has been previ-
ously highlighted as a challenge to making PBSI more generalizable [71]. Implantation
accuracy is crucial to implant quality because, unlike when using an afterloader, there
is no opportunity to correct for misplacement by varying dwell times or positions [73].
Furthermore, the use of lower-energy 103Pd makes the dose distribution more sensitive
to misplacement than implants of 125I used in prostate brachytherapy [78]. Poor visibil-
ity of implanted seeds under 2D US has been described [79] and a learning curve eﬀect
reported with respect to dosimetry [72], highlighting the eﬀect of the operator’s skill
and experience on implant quality. Even with an experienced operator, a recent study
of seed placement error found a mean (±SD) seed error of 9 ± 5mm between planned
and implanted positions, with 5 out of 20 implants falling short of desired dosimetric
coverage [80]. These error magnitudes compare unfavourably to those reported for LDR
prostate brachytherapy of 3 ± 6mm [80]. Additionally, seeds have been shown to migrate
between implantation and two-month follow-up, with a tendency to coalesce, resulting
in hot spots in the implants, although the distance migrated by individual seeds was not
evaluated [72].
Historically, operator dependence has played a significant role in determining the
success of APBI brachytherapy techniques, impeding the dissemination of interstitial
approaches [34] while catapulting the adoption of intracavitary ones [13]. The challenging
nature of the interstitial approach has been blamed for its poor adoption [15], with
its use limited primarily to high-volume centres [13]. The first intracavitary device,
the Mammosite applicator, was developed explicitly to simplify breast brachytherapy
with the goal of making it more widely available [81]. In stark contrast to the limited
adoption of interstitial brachytherapy, over 40,000 intracavitary devices were sold even
before 5–year data on safety and efficacy was available [34]. The success and failure of
prior APBI approaches with respect to adoption underscores the importance of addressing
operator dependence in PBSI. Simplifying and streamlining the procedure is not simply
a matter of convenience or efficiency, but rather a prerequisite for its widespread use.
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Work to date addressing operator dependence and reproducibility of the procedure
has included changes to the workflow of the procedure [71, 82], and previous development
of a custom imaging system [83]. The current approach of using a fiducial needle and
template was itself the result of early experimentation by the pioneers of the technique
to improve on freehand needle delivery, finding a reduction of seed placement error in
a phantom study [82]. More recently, the Kelowna group improved reproducibility of
patient setup by using a same-day CT simulation and by positioning the template support
prior to sterilizing the surgical area when the absence of surgical drapes makes support
adjustments easier to make [71].
The eﬀect of visualization diﬀerences between CT and US on planning and dosimetry
has also been explored using co-registered images of the seroma in CT and 3D US. Simu-
lated shifts in the delivery of treatment plans based on diﬀerences in centroid between the
two modalities were found to decrease mean coverage (V100) of the CT defined PTV by
10% [84]. The authors recommended incorporation of 3D US into the planning procedure
to account for the documented diﬀerences and found that delivery of the treatment plan
to the combined PTV of both modalities was a viable option.
Lastly, a purpose-built imaging device has previously been proposed for PBSI in the
form of a gamma camera. Designed to evaluate seed positions post-implantation, the
proposed clinical device would use a pair of planar gamma cameras to capture 2D images
based on the emitted photons of the seeds from orthogonal perspectives and use both
images to triangulate the seed positions in three dimensions [83]. Images of an anthro-
pomorphic phantom using a simplified prototype of the device, consisting of one camera
and a repositioned phantom rather than two orthogonal cameras, was able to localize
seeds within 30 seconds with a median error of 1mm [83]. However, the device requires
combination with a second, anatomical imaging modality (e.g. ultrasound) to relate seed
positions to the target volume. Additionally, despite the obvious utility in intraoperative
assessment, intraoperative guidance provided by the device is limited to the influence
that knowledge of already implanted seeds has on the implantation of subsequent seeds,
rather than oﬀering implantation guidance prospectively.
Despite the valuable contribution of past researchers in this area, the problem of
improving the simplicity and repeatability of PBSI remains unsolved.
1.3.2 Limitations of Intraoperative Guidance
The current approach of using freehand 2D US for intraoperative guidance poses two
primary limitations: the lack of a fixed reference for implant coordinates during the
procedure and challenges related to interpreting 3D anatomy from 2D images.
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During LDR prostate brachytherapy procedures, both the transrectal ultrasound
probe and the needle template are mounted to a “stepping” support, capable of finely ad-
justed translations on a stable platform. The use of a common support for the template
and US probe allows the two to be co-registered and projections of the needle template
overlaid on the live ultrasound image [67]. In this way, a series of fixed references (needle
template projections) are visible at depth with respect to the target volume (prostate).
The position and orientation of 2D transrectal ultrasound (TRUS) images can be reliably
related to each other based on the known motion of the stepper.
Conversely, in PBSI, the position of ultrasound images with respect to the needle
template is only approximately known and until the fiducial needle is placed there is no
fixed reference. Even after the fiducial needle is placed, its use as a reference is impeded
by ambiguity in the orientation of the US image with respect to the template and by
an inability to identify the distance of the image from the fiducial tip when the fiducial
needle is viewed in cross-section.
The lack of a robust fixed reference during the procedure makes it difficult to relate
intraoperative US images to the coordinates of the planned implant. Without being
able to precisely relate observed needle and seed positions to intended ones, opportun-
ities for intraoperative feedback are limited, contributing to the difficulty and operator
dependence of the procedure.
In addition to the lack of a fixed reference, the interpretation of 3D anatomy from a
2D imaging modality has well documented limitations [85]. The process of interpreting a
3D structure from a series of 2D images requires that the operator mentally transform the
2D images to gain an impression of 3D anatomy, a process that is both time-consuming
and subjective [85]. Additionally, practical limits on probe positioning make certain
image orientations difficult or impossible to view, such as planes parallel to the skin
surface. Lastly, the ambiguity of needle position and orientation when viewed in cross-
section under 2D US limits the ability to compare needle positions to other landmarks
(e.g. local anatomy, other needles) unless those landmarks are visible with the needle
trajectory in-plane with respect to the image. Together, these limitations of 2D US also
contribute to the procedure’s operator dependence.
1.3.3 Imaging Dissimilarities Between Planning and Guidance
In addition to the challenges posed by limitations of intraoperative guidance, ad-
ditional complexity is added by the dissimilarities between guidance (intraoperative)
imaging and planning (preoperative) imaging. The two major contributors to those dis-
similarities are diﬀerences in modality and time.
1.3. Challenges of PBSI 21
The current use of two diﬀerent imaging modalities, CT for planning and US for
guidance, creates dissimilar images that makes comparing intraoperative images to the
preoperative plan more challenging. Images diﬀer both in their appearance; such as the
interpretation of bright/dark regions, contrast and texture; as well as the anatomical
information contained.
With respect to anatomical information, the vastly diﬀerent sources of the contrast
observed in CT and US means that the information contained in images from each modal-
ity is fundamentally diﬀerent, irrespective of how that image is represented. For instance,
in current practice, target volumes are defined based on contours of the seroma and sur-
rounding fibrosis [27], both of which are visible under CT. Conversely, ultrasound images
allow for visualization of only the fluid-filled cavity and not the surrounding fibrosis [86],
likely explaining why seroma volume studies have found smaller average seroma volumes
when contouring in 3D US than in CT [87]. In addition to diﬀerences in size, diﬀerences
in position have also been documented, with mean (±SD) centroid shifts of 7 ± 3mm
[84]. As a result, identifying movement or deformation of the seroma and diﬀerences
between actual and planned implants is confounded by diﬀerences in what can be seen
in each modality.
In addition to the information content of each modality, more superficial diﬀerences
in image appearance between modality, such as the reversal of seroma contrast (bright in
CT, dark in US), limited slice thickness in CT, and speckle pattern in US also complicate
the comparison of pre- and intra-operative images. Comparison is further complicated by
a relative dearth of anatomical landmarks other than the target volume, such as would
be provided by the urethra, bladder and rectum in prostate brachytherapy procedures.
The separation of pre- and intra-operative imaging with respect to time presents an-
other source of dissimilarity between planning and guidance. Breast tissue is both mobile
and deformable, presenting the opportunity for considerable motion between imaging ses-
sions. A portion of this motion error is mitigated by using consistent protocols for patient
positioning during planning and implantation [71], and through the addition of a same
day simulation in order to minimize the time between imaging sessions [71]. While these
protocols mitigate diﬀerences introduced by temporal separation, some residual error is
unavoidable. Additionally, anesthesia induced tissue sag is present during the procedure
but absent during the planning process. Although a laser levelling system and skin tat-
toos is used to account for shifts in patient position [71], internal or non-rigid motion is
currently unaccounted for.
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1.4 Thesis Objective
To address the operator dependence of PBSI, we propose the use of an intraoperative
3D US guidance system. Thus, the objective of this thesis is to develop and validate
a 3D US guidance system that can be used during PBSI with minimal disruptions to
the clinical workflow and to demonstrate the utility of the system in a proof-of-concept
phantom procedure. By developing this system, we aim to simplify and streamline PBSI
to make it easier for clinicians to adopt, with the ultimate goal of improving the available
radiotherapeutic options for women with early stage breast cancer.
1.5 Relevant Physics: Brachytherapy and 3D Ultrasound
1.5.1 Brachytherapy Physics
As discussed in section 1.1.3, brachytherapy makes use of radioactive sources placed
adjacent to the irradiation target. The relevant physics of energy deposition and distri-
bution in this context are described below.
Radioactive decay of brachytherapy source material produces decay products charac-
teristic of the source material. Most commonly used brachytherapy sources are gamma
emitters, which produce photons of characteristic energies determined by the process(es)
of disintegration for a given isotope.
In the case of permanent implants, where activity changes considerably over the
course of treatment, the activity of the source and thus the dose rate delivered falls as
the material decays but the photon energies remain the same. As a result, the relative
spatial distribution of the dose also remains constant with time. That spatial distribution
of dose is calculated for the purposes of planning and evaluating treatment according to
the American Association of Physicists in Medicine task group 43 (TG43) formalism
[88]. The TG43 formalism uses experimental data as the basis for generation of source-
specific data tables used in a formula that summarizes the eﬀects of attenuation in the
surrounding material, anisotropy due to internal seed construction and angle-dependent
eﬀects of self-filtering as gamma rays exit the seed [88, 89]. The TG43 formalism models
the surroundings of the seed as a homogeneous region of water and calculates the total
dose resulting from multiple sources or source positions as the sum of their individual
dose contributions. TG43 calculations make the simplifying assumption of ignoring inter-
seed attenuation and, unlike dosimetry of external beam radiotherapy, ignores the eﬀects
of radiation scattering.
Clinically, the geometric distribution of dose around the source exhibits rapid fall-oﬀ
due to the low energies used relative to external beam radiotherapy. This rapid fall-oﬀ
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in dose allows for sparing of nearby normal tissue at the cost of making requirements
for treatment accuracy more stringent [23]. As an illustration of the dose fall-oﬀ in
103Pd seeds, for two commercial models of cylindrically shaped seeds, dose rates 2.5 cm
perpendicularly from the seed centre were <50% of the dose rate 1 cm from the seeds,
falling to <10% at a distance of 5 cm [88].
1.5.2 Three-Dimensional Ultrasound Physics
Medical ultrasound is an imaging modality that uses focused pulses of acoustic energy
to generate images of internal anatomy. Pulses of sound are generated by piezoelectric
crystals in the ultrasound probe, or transducer, that reflect oﬀ of internal structures. A
portion of those reflections return to the transducer and the piezoelectric crystal produces
a signal. Using an assumed speed of sound in tissue of 1540m/s and the time diﬀerence
between sending and receiving the reflected pulse, the depth of the scattering structure
that produced the reflection can be inferred. Historically, information along a single scan
line, the path traversed by one pulse, could be displayed as an ‘A-mode’ scan. In modern
systems, multiple ‘A-mode’ scans are performed along adjacent trajectories to create a
‘B-mode’ scan, displayed as a 2D grayscale image.
The geometry of adjacent trajectories in a B-mode scan and the mechanisms for
producing them give rise to three categories of transducers: linear array, curved array,
and phased array transducers [90]. In a linear array, transducer elements are arranged in
a linear, 1D array with a subset of the elements used to generate a given scan line. By
shifting the subset of elements used along the length of the array, a series of parallel scan
lines are generated, resulting in a rectangular image with constant lateral resolution [90].
Conversely, a curved array also uses a 1D array of elements but with the elements arranged
in a line that curves convexly. The result is a series of diverging scan lines that produce
a pie-slice-shaped image, providing a larger field of view than a linear array, particularly
at large depth settings, at the cost of a lateral resolution that worsens with increasing
depth [90]. Lastly, a phased array uses beamforming to determine the direction of the scan
line, introducing temporal delays between elements in the transmission and reception of
ultrasonic pulses to change the direction of the wave produced by constructive interference
between pulses from diﬀerent elements. Images from phased arrays are approximately
triangular and allow for images to be captured with a reduced transducer footprint,
particularly important for applications where the acoustic window is limited (e.g. imaging
through the space between adjacent ribs) [90]. In the context of PBSI, a relatively small
and superficial target is to be imaged without constraints related to an acoustic window.
As a result, a linear transducer is used.
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While the path of each sound wave through the tissue may be thought of as a line,
the sound wave passes through a column of tissue with finite size in all three dimensions,
with the resulting image influenced by all the material contained within it. Furthermore,
the shape of that column varies as a function of distance away from the probe, starting
relatively wide at the probe, tapering to a minimum as it reaches the focal depth of
the image and widening again beyond the focal depth. The result is a resolution in
the lateral and elevational directions that varies with depth, reaching an optimum at
the focal depth. Conversely, the axial resolution, determined by the duration of the US
pulse, remains constant. Multiple transmit zones may also be used in which a composite
image is formed from repeated pulses along the same path at diﬀerent focal depths to
improve the lateral and elevational resolutions.
Extending these principles to 3D US imaging can use one of three strategies: 1) 2D
arrays, in which the 1D array of transducer elements used in 2D imaging is repeated
to create a 2D grid for 3D imaging; 2) using an external sensor to track position and
orientation of a freehand 2D US transducer and reconstructing a 3D image from the
2D images and their known positions in space; or 3) through the use of a mechanical
approach, which mimics the position sensing strategy to reconstruct a 3D image from
many 2D images but uses a mechanical or robotic actuator to constrain probe motion
along a predetermined path [91].
Three-dimensional scanners using the mechanical approach may be further described
by the motion of the US transducer as either linear, tilt/rotational, or hybrid scans, com-
bining both linear and rotational motion simultaneously. In the case of the solution to be
described in subsequent chapters, a mechanical 3D US system using a hybrid geometry
has been developed. The hybrid geometry employed combines a linear translation and
outward tilt, with linear and rotational motion maintaining a constant proportion: thus,
all adjacent slices have equal linear and angular separation. The resulting spacing of
2D slices creates worsening elevational spacing with increased distance from the trans-
ducer due to the tilt component of the scan. Although the elevational direction of the
transducer changes with tilt angle, for convenience the axes of the reconstructed scan
may be described according to the axial, lateral and elevational directions of the 2D US
transducer when the tilt angle is 0°.
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1.6 Ultrasound Guidance of Brachytherapy Procedures
1.6.1 Three-Dimensional US Guidance of Prostate, HDR Breast Brachy-
therapy
Three-dimensional US has been previously used in the guidance of other brachy-
therapy procedures, including prostate brachytherapy, gynecological brachytherapy and
interstitial breast brachytherapy. Bax et al. [92] developed a prostate guidance system
that used a mechatronically rotated TRUS probe to capture a 3D image. In addition to
using 3D US, the typical use of a co-registered needle template was extended to a co-
registered mechanical linkage, creating a dynamic needle guide that allowed for oblique
insertion [92]. Proof of concept work has also been performed using a mechatronically
rotated TRUS probe for gynecological brachytherapy [93], as well as a 360° transvaginal
US system for the same application [94].
In the case of interstitial breast brachytherapy, Poulin et al. developed a 3D US
guidance system that used variable mounting positions and one degree-of-freedom of live
tracking to register it to the compressive plates typically used in the procedure. Use
of the system would potentially allow a CT scan to be avoided, streamlining patient
workflow [95]. To prevent artifacts caused by probe motion, a thin plate of acoustically
translucent polymethylpentene (TPX™) plastic is placed between the probe and the
breast [95]. Despite being tailored to the needs of breast brachytherapy, its reliance on
the presence of compressive templates on either side of the breast makes it inappropriate
for the guidance of PBSI without further modification.
1.6.2 Other Methods of Needle and Needle Template Tracking and Guid-
ance
While numerous mechatronic 3D US systems have been developed for needle guidance,
other approaches to needle and needle template tracking exist, including the use of CT
and magnetic resonance (MR) imaging techniques, optical tracking and pielectromagnetic
(EM) tracking.
In the context of gynecological brachytherapy, guidance techniques using MR and
CT imaging have been developed including iterative imaging following insertion of each
needle, either with MR [96] or CT [97], as well as with near real-time (0.67Hz) 0.5T
MR used intraoperatively [98]. For all of these techniques, specialized equipment and a
time-consuming workflow pose major limitations to widespread adoption.
Optical tracking of tools has been widely adopted for various image guided interven-
tions and is the most established modality in tracking devices for image guided interven-
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tions [99]. Despite its widespread use, optical tracking suﬀers from a reliance on line of
sight and would represent a relatively bulky complication to the operating room.
Electromagnetic tracking, which has the advantage of not requiring line of sight, has
been applied to interstitial breast brachytherapy for insertion guidance [100], catheter
reconstruction [101], and quality assurance [102]. However, the use of pre-loaded needles
in PBSI would prohibit placement of sensors at the needle tips. Placement of sensors on
the US transducer and needle template would be possible, but add considerable cost and
complexity as a result of the specialized equipment and calibration protocols.
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Chapter 2
System Development and Validation
2.1 Introduction
The standard of care for early stage breast cancer is breast conserving therapy (BCT)
[1], consisting of lumpectomy followed by whole breast irradiation (WBI) in fractionated
doses over 3–7 weeks [2]. Despite cancer recurrence rates equivalent to mastectomy
while preserving the breast [3], BCT may be underutilized, with some patients opting
instead for mastectomy in order to avoid radiation [4], a decision often influenced by
the lengthy duration of WBI [5]. These findings have contributed to an active area of
research in accelerated partial breast irradiation (APBI) in an eﬀort to reduce the burden
of treatment and increase access to care.
Permanent breast seed implantation (PBSI) is one of a variety of APBI techniques
that have been developed [4, 6]. PBSI delivers low-dose-rate brachytherapy using perman-
ently implanted Palladium-103 (103Pd) seeds during a single procedure lasting 1–2 hours
[7, 8]. By using permanently implanted seeds, radiation procedure time is reduced to a
single visit with radiation dose to the heart and other organs at risk minimized [9]. Seeds
are implanted on an outpatient basis, with seed placement planned using pre-operative
x-ray computed tomography (CT). In the current workflow [2], intraprocedural guidance
is provided by live freehand 2D ultrasound (US), using a template in an articulated arm
and adjusted for the chosen angle of entry. A non-seed-bearing ‘fiducial’ needle acts as
an US landmark.
Follow up of 134 PBSI patients showed 5–year recurrence rates similar to the ex-
pected outcomes for WBI with an improved side eﬀect profile [2]. Despite positive out-
comes, post-implant assessment of 20 PBSI patients showed a mean (±SD) diﬀerence of
9 ± 5mm between planned and implanted positions, comparing unfavorably to the es-
timated 3–6mm accuracy achieved in permanent seed prostate implants [8]. Some cases
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indicated a systematic bias in implant position, suggesting issues related to setup repro-
ducibility [8]. Acceptable dosimetry has been reported for PBSI, with the volume of the
evaluative PTV (seroma + 0.5 cm) receiving 100% of the prescribed dose being 91% for
the first 25 patients treated in an early cohort, increasing to 95% for the final 10 [10].
However, technical challenges such as the use of diﬀerent image modalities in the planning
and guidance of the procedure, and the lack of a registered coordinate system for needle
guidance at depth, such as the co-registered US stepping unit present in prostate implant
procedures, represent areas for improvement [8]. In addition to implantation accuracy,
standardization and reproducibility of the procedure have also been highlighted as an
area of research, with the goal of making PBSI more easily adopted [11].
Previous improvements to the workflow and accuracy of the procedure have been
limited to the use of needle template guidance and checks of patient alignment [11, 12].
Pignol et al. improved upon free-hand needle insertion using a template and fiducial
needle [12], while Batchelar et al. incorporated a same-day CT simulation and intraoper-
ative physical checks using a room laser and external markers [11]. These intraoperative
checks assist in setup positioning but cannot account for non-rigid breast deformation and
still require imaging to locate internal targets. A gamma camera system to intraoperat-
ively locate implanted seeds has also been explored [13, 14], however its use as a guidance
tool is limited to identifying seed displacements rather than minimizing displacements
prospectively and would require additional development to integrate it with a second,
anatomical imaging modality [14]. Despite these prior works, the unmet needs of a re-
producible technique with fixed reference and common-modality planning and guidance
persist.
Similar needs have been previously addressed for permanent seed prostate brachy-
therapy [15] and breast multicatheter interstitial brachytherapy (MIB)[16] using US sys-
tems with registered needle guides. In prostate brachytherapy, the standard delivery
method uses a mechanical stabilizer that supports both a transrectal US (TRUS) probe
and a co-registered needle template. Co-registration of the template allows projections
of the needle template positions to be overlaid on the TRUS images, providing a fixed
reference at depth during the procedure [17]. Numerous groups have developed robotic
systems to extend the technique to 3D US imaging [18].
The breast MIB guidance system developed by Poulin et al. used an analogous ap-
proach to prostate brachytherapy, registering a needle template to a robotic 3D US
scanner [16]. The registered needle guide consisted of two parallel plates compressing
the breast on the medial and lateral aspects. The scanner was fixed between the plates
and tracked in one rotational degree-of-freedom (DoF) using an encoder, with a second
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translational DoF provided by multiple mounting positions. A thin plate of sonulu-
cent polymethylpentene (TPX™, Mitsui Chemicals, Tokyo, Japan) plastic, acoustically
coupled with US gel on both sides, was positioned between the 2D probe and the breast
to prevent motion artifacts due to probe movement. The system facilitated intraproced-
ural planning, allowing a pre-implant CT to be omitted. Though suitable for planning
and guidance of MIB breast brachytherapy, the system described by Poulin et al. relies
on compressive, parallel plates used in MIB but not in PBSI. Since PBSI is delivered to
an unconstrained breast, registering the scanner and template requires six DoF’s rather
than two and accommodation of greater distances between the scanner and template.
Alternate approaches to catheter guidance include electromagnetic (EM) tracking
and the use of intraoperative magnetic resonance imaging (MRI) guidance. EM tracking
has been previously proposed for catheter reconstruction in HDR brachytherapy [19],
including breast [20, 21] and prostate brachytherapy [22]. However, the use of pre-
loaded needles in PBSI presents a considerable complication with respect to placement
of EM sensors on the needles. Intraoperative MRI has been previously used to guide
gynecological brachytherapy [23, 24], however the cost and complexity of specialized
facilities required would pose major limitations to clinical adoption.
To address the additional technical requirements, we have developed a 3D US guidance
system with the necessary DoF’s and range of motion for template tracking in PBSI. We
propose use of the system in PBSI with the goal of improving the accuracy and decreasing
operator dependence of the implant procedure. To our knowledge, there have been no
prior reports of a patient or phantom PBSI procedure guided with intraprocedural 3D
imaging. In this thesis, we present the development and validation of the guidance
system, culminating with its use in a phantom procedure.
2.2 Materials and Methods
2.2.1 System Design
The system consists of three components: 1) a 3D US scanner, 2) an encoded tracking
arm mounted to the scanner, and 3) a needle template with fiducial divots at known
locations. With the scanner and needle template held in fixed positions, the tracking
arm is used to locate the template fiducials, registering the needle template (Figure
2.2a).
2.2.1.1 Three-Dimensional US Scanner
The 3D US scanner uses a modification of the previously described assembly developed
for breast MIB [16]. Briefly, a motorized scanner sweeps a 2D US probe through a pre-
defined ‘hybrid’ motion, combining 5 cm of linear translation and 60° angular tilt. A
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connected personal computer (PC) controls the scanner and reconstructs 150 2D images,
each separated by 0.33mm and 0.4°, into a 3D image with an approximately trapezoidal
cross-section (Figure 2.1) and width equal to the width of the 2D images. While the
scanner can be adapted to any 2D US system and transducer, experiments were conducted
using a Phillips iU22 US system with an L12-5 linear transducer (Philips Ultrasound,
Bothell, USA). Reconstructed voxel size increased with increasing depth setting, ranging
from 0.07–0.13mm in the lateral and axial directions, and 0.17mm in the elevational
direction. The field of view is 50mm wide with a height equal to the depth of the
2D images (40–80mm) and length equal to the sum of the scanner’s linear translation
and the 2D image depth (90–130mm, total). The scanner’s frame rate is set to be
slower than the 2D US system to avoid repeated frames, causing scan time to vary
from 10–18 seconds depending on depth and other settings of the 2D system. Image
reconstruction is performed continually during image acquisition and the 3D image is
available immediately after scan completion. During use, the scanner is rigidly held by
an adjustable, counterbalanced mechanical arm.
2.2.1.2 Encoded Arm and Modified Needle Template
The needle template is intermittently tracked in order to register it to the 3D US
image, allowing a 3D visualization of the needle template and projections of the needle
trajectories onto the 3D image to be displayed on a PC during the procedure (Figure
2.1). Template holes have a grid spacing of 5mm and are sized to accommodate 18 gauge
needles (1.27mm diameter) with the exception of the centre position, sized for 17 gauge
needles (1.47mm diameter), matching clinically used seed-bearing and fiducial needles,
respectively.
Template registration is accomplished using a passive mechanical tracking arm moun-
ted to the 3D US scanner (Figure 2.2a). The tracking arm has three, 3D printed nylon
segments that each rotate at a one DoF joint, with the arm segment most proximal to
the scanner 30mm in length and the remaining two segments 65mm each. Each joint is
tracked by a 12-bit magnetic encoder and measurements communicated to the PC using
a BEI USB sensor interface (BEI Sensors, Thousand Oaks, USA), allowing the position
of the arm to be calculated. The end eﬀector of the arm is a stainless-steel ball 12.7mm
in diameter that seats into conical, fiducial divots on a modified needle template. By
measuring the positions of four non-collinear divots, the needle template is registered
with the 3D US image by rigid, homologous-point-based (landmark) registration [25].
Once the template is registered, the arm may be folded against the scanner.
Material costs of the tracking arm, including encoders, sensor board and the 3D
printed segments, are in the hundreds of Canadian dollars.
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Figure 2.1: Screenshot from guidance software showing registered needle template re-
lative to central slice of 3D US image and segmented seroma phantom (green). Teal
cylinder indicates projection of selected needle template position.
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Figure 2.2: a) Image of guidance system positioned above commercial breast phantom.
b) Illustration of coordinate systems (CSs) used in validation (‘Image’ CS not shown).
2.2.2 System Calibration and Validation
The validation strategy for the system and its components is summarized in Figure
2.3, outlining the flow of information through the system and the experimental validation
of each step. An additional experiment validates the system as a whole by guiding a mock
procedure in a phantom. The constructed system and an illustration of its coordinate
systems (CSs) are shown in Figure 2.2b. Axes of the template CS are parallel with the
template grid and its origin aligned with the centre template position. The arm CS has
its Z and Y axes parallel with the rotation axes of the first and second joints, respectively,
and its origin at the point on the first joint axes closest to the second joint axis. The
axes of the scanner CS are parallel with the lateral, axial and elevational axes of the
2D US transducer when centred and the CS origin on the bottom surface of the TPX
plate. Axes of the reconstructed 3D US image (image CS, not shown) are approximately
parallel with those of the scanner coordinate system and its origin at the centre of the
X-Z image plane closest to the probe, such that the two CS’s are nearly coincident.
2.2.2.1 Three-Dimensional Image Reconstruction
The generated 3D image was tested for accuracy of the reconstruction and for in
vivo suitability of the scanner. Linear measurements were validated using a previously
described [26] phantom consisting of four parallel layers of strings, each 10mm apart.
Each layer of the phantom is arranged in a 10mm by 10mm grid pattern and immersed
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Figure 2.3: Summary of information pipeline in the guidance system and the list of
experiments used in validation. Experiments 1–6 validate a step in the process indicated
by dashed arrows. Experiment 7 evaluates the process as a whole. CS = coordinate
system.
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in a water-isopropanol bath (7.25% isopropanol by volume) in order to match the nominal
speed of sound in tissue, 1540m/s [27]. Scans were taken of the immersed phantom at six
depth settings (40, 45, 50, 60, 70 and 80mm, respectively) and 40 manual measurements
of the distance between adjacent, parallel strings were taken per direction per depth
setting in the lateral and elevational directions. Axially separated strings are oﬀset to
prevent shadowing and measurements in this axis taken between perpendicular strings.
Volumetric validation was performed by scanning and manually segmenting two ser-
oma-shaped agar phantoms and comparing segmentation volume to measured water dis-
placement. The seroma-shape of the phantoms was created by forming the agar in 3D
printed moulds matching seroma contours of 3D US scans of 2 PBSI patients. Contoured
3D US images were captured using an optically tracked, 2D US transducer (RESTITU
Platform, Resonant Medical Inc., Montreal, Canada). Phantom material consists of an
agar and glycerol mixture (by mass, 3% and 8%, respectively) having a speed of sound
of 1540m/s at room temperature [28]. No scattering agent was added to the seroma
phantom, simulating the hypoechoic appearance of a seroma under US, while 3 g/l of
SigmaCell cellulose (Sigma-Aldrich, St. Louis, USA) was added to the background ma-
terial to create contrast and simulate the surrounding breast tissue. Phantoms were
scanned using the developed 3D US system, resampled at 1mm intervals and manually
contoured using 3D Slicer [29]. Contour volumes were compared to water displacement
measurements, each of which was repeated 4 times per phantom.
In–vivo image quality was assessed using breast scans taken of one healthy female
volunteer. Scans were captured in accordance with the University of Western Ontario
Institutional Review Board approved protocol by an experienced ultrasonographer who
provided qualitative feedback on image quality, acoustic coupling, and device usability.
2.2.2.2 Encoder Mapping
For each tracking arm encoder, errors were mapped and corrected for to improve the
accuracy of the tracking arm. Encoders were calibrated by mounting each segment of
the arm above a surface plate and correlating encoder measurements with known angular
geometries to create a calibration table.
To provide known geometries, a unique setup was required for each joint. For the joint
most distal to the base of the arm, the arm’s existing spherical tip was placed on top of
gauge blocks to set the tip’s height above the surface plate and the height of the joint was
measured with a height gauge (Figure 2.4a). The angle of the joint with respect to the
surface plate was calculated from geometry, providing a known angle. When calibrating
the middle joint of the arm, the calibration process was repeated with the most distal
segment removed and a tooling ball inserted in its place (Figure 2.4b, left). Finally, the
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Figure 2.4: Encoder mapping set-up. a) Surface plate, gauge blocks and height stand
in use during calibration of the most distal joint. b) Partially disassembled template
tracking arm with tooling balls. The most distal segment (left) has been removed and a
tooling ball added in its place. A machined extension and tooling ball (right) has been
added.
most proximal joint was calibrated by attaching a machined extension 35mm in length
with a tooling ball at its end to the base of the arm (Figure 2.4b, right), such that the
extended length was equal to the other segments of the arm (65mm). For all joints,
gauge block heights and encoder readings were recorded in approximately 1° intervals of
joint motion by making variable increments in gauge block height.
The sensitivity of angle to gauge block height increases as the joint angle approaches
vertical, making this calibration method suitable for only a limited angular range (ap-
proximately ±80° from horizontal). To span the full range of each joint, 3–6 diﬀerent
mounting positions were used per encoder to take measurements in overlapping regions
of the encoder’s range.
An integral error oﬀset was calculated between mounting positions by interpolating
data in overlapping regions to create corresponding points between two mounting posi-
tions and computing the mean diﬀerence between them. Encoder mapping produced a
plot of each encoder’s integral (accumulated) error as a function of encoder position with
the integral arbitrarily beginning from the first position measured.
Once the integral error of each encoder was measured, the result was smoothed using a
moving average filter 30 encoder counts (nominally 2.6°) wide and interpolated to create
a look-up table of corrected angles. The accuracy of the resulting look-up tables was
evaluated during the point-localization accuracy experiment, described in Section 2.2.2.3
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Figure 2.5: Guidance system positioned in tracking arm calibration jig. Jig contained
45 fiducial divots arranged in a 9 × 5 grid pattern separated by 2 cm in each direction.
Mounting position of scanner adjusted forward/back and left/right in 3 cm increments,
so that 180 (45 × 4) known positions are available for calibration/validation.
below, by comparing the point measurement error with the correction tables implemented
to errors with the naïve encoder interpretation.
2.2.2.3 Tracking Arm Point Accuracy
With the encoders calibrated for angular accuracy, the next step in the flow of in-
formation (Figure 2.3, experiment 3) was using those angles to determine arm position.
Point measurement accuracy of the arm was assessed using a machined test jig with 45
fiducial divots placed at known positions on two planes (Figure 2.5). The divots were
regularly spaced on a grid with 2 cm separation of 9 rows and 5 columns: 4 rows on the
horizontal plane, 4 rows on the vertical plane, and one row at the intersection of the two.
The scanner and attached arm were mounted to the jig by the scanner’s TPX™ plate,
with the plate parallel to the horizontal plane at a 7.5 cm elevation. This configuration
placed the divots approximately where a needle template would be placed relative to the
scanner during a procedure.
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Additionally, the mounting position of the scanner was adjusted to four positions on
the jig, forward/back and left/right, separated by 3 cm in each direction. The 3 cm dif-
ference in mounting positions and 2 cm divot spacing ensured that divot positions relative
to the scanner were unique for each mounting position, creating 180 locations for testing
from the 45 physical points. Of the 45 physical points, 15 were used for calibration and
30 for validation, with all fiducial points measured three times per mounting position.
Calibration was performed by solving for the location of each measured point in the arm
CS (Figure 2.2b) based on measured encoder values. Points in the arm CS were rigidly
registered to a reference point cloud in the scanner CS, describing the known positions
on the jig, by landmark registration. Forward kinematics of the arm requires the encoder
measurements at which the 2nd and 3rd arm segments are parallel to the 1st segment,
referred to as the ‘zero-points’, to be known. Zero-points of the 2nd and 3rd encoders were
found by minimizing the root mean squared error (RMSE) of the transformed calibration
points using an exhaustive search strategy in the region around an initial approximation
(± 40 encoder counts, nominally ± 3.5°; search resolution of 1 encoder count) and fiducial
registration error (FRE) [30] of the resulting registration was reported. Selection of a
zero-point for the 1st encoder was not optimized as it corresponds to a DoF in the arm
to scanner registration and thus does not aﬀect measurement accuracy.
With the arm calibrated, its zero-points and registration to the scanner were then
used to determine the measured position of the validation points and compare them to
their known positions. Results of the validation were assessed by calculating the target
registration error (TRE) [30] of the validation points and assessed for bias by reporting
95% confidence intervals on the mean error components in each axis of the arm CS.
2.2.2.4 Image to Scanner Registration
Scanner and imaging CSs were registered by imaging intersections of a string phantom
mounted in a known position relative to the scanner (Figure 2.3, experiment 4). The
phantom consists of three layers of strings with 1 cm axial separation. Each layer consists
of four strings arranged to form a 2 cm by 2 cm square, with subsequent layers oﬀset
±1 cm in both axes parallel to the layer to avoid shadowing the layers below. Of the 12
intersection points, six were chosen as fiducials, consisting of two opposing corners of each
layer, alternating in position between layers, with the remaining six used as targets. The
phantom was immersed in the aforementioned isopropyl alcohol solution and scanned at
each of the six depth settings described (Section 2.2.2.1).
To minimize localization error, intersection points were found by modelling each string
as a line in 3D space and solving for their least squares intersections. To develop the 3D
line models, 3D Slicer [29] was used to resample the image at 2.5mm intervals along the
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length of the string and points were manually placed in all planes where the string was
clearly visible. A 3D line of best fit through these points along each string, and their
corresponding intersections, was then calculated using MATLAB R2016a (MathWorks,
Natick, USA). Rigid registration between the scanner and image CSs was computed
by landmark registration. Following registration, scanner-to-image transformations were
separated into translation vectors and rotation angles about the axes of the scanner CS
and both FRE and TRE were calculated.
2.2.2.5 Template Localization Accuracy
With the tracking arm calibrated and registered to the image, the process of register-
ing the needle template using its fiducial divots could be validated (Figure 2.3, experiment
5). A test jig was constructed in which the scanner and needle template were mounted
in known locations. The needle template was localized first using measurements from
the localizing arm and second from the known position of the fiducial divots on the jig.
Error at each fiducial was assessed by comparing their measured and actual locations.
Overall error of the resulting registration was assessed by determining the rigid rotation
and translation describing the registration error (TError), defined as,
TError = (TActual)−1 × TMeasured (2.1)
where TMeasured is the measured transform between template and scanner CSs and TActual
is the ground truth transform based on the geometry of the test jig. TError was then
separated into a translation vector and rotation angles in each axis. Registration was
repeated for five sets of template measurements with the template remaining in the same
position for all five.
2.2.2.6 Needle Insertion Accuracy
With the 3D US scanner and template tracking arm calibrated and registered, its
overall targeting accuracy could be assessed by measuring agreement between the two
sub-systems. The needle template was registered and needles inserted to a known depth
through the template into a bath of isopropyl alcohol solution (described in Section
2.2.2.1) before being scanned. Needle positioning error was found by comparing the
needle trajectory and tip position in the 3D US image with that expected from template
tracking and insertion depth.
In order to image the inserted needles, the scanner was positioned such that its ima-
ging surface was submerged while the motor housing was not (Figure 2.6). A cylindrical
plastic sleeve was placed over the tracking arm to prevent damage in case of accidental
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Figure 2.6: Experimental set-up for needle insertion through a tracked template. A
collar affixed to the needle allows for a known insertion depth into a bath of isopropyl
alcohol and water. Comparison of needle position in tracking and imaging quantifies
tracking accuracy. Tracking arm has been bagged to prevent damage if immersed.
immersion. Insertion depth was controlled by fixing collars to the needles to create a
physical stop at the surface of the template. Collar position was measured with callipers
prior to insertion and averaged over three repeated measurements.
Tracked needle insertion was repeated at four needle insertion depths and five tem-
plate positions. Template positions were chosen to define the four corners of a rectangle
50mm wide and 30mm tall centred on the needle template. The width and height of this
rectangle were chosen by examining ten PBSI radiation treatment plans and finding the
mean dimensions of the planned needle positions, rounded up to the nearest 5mm incre-
ment. The fifth template position was immediately above the centre (fiducial) position
of the template. Needle insertion depths were selected as 11, 13, 15 and 17 cm in order
to span the range of insertion depths estimated from 25 PBSI patients (planned depth
in tissue + needle template thickness; range: 10.8–17.4 cm, median 12.8 cm). For each
insertion depth, the template was positioned such that the needle tip was visible within
the 3D US image for all five hole positions without adjusting the template or scanner.
Apparent tip positions and trajectories in the 3D images were determined by manually
placing one point at the needle tip and another along the needle shaft at the furthest
visible position from the tip. Points at the tip and shaft were averaged across three
repeated placements per scan each separated by at least 24 hours. Additionally, repeated
2.2. Materials and Methods 51
needle tip placements were used to calculate fiducial localisation error (FLE) [30].
2.2.2.7 Phantom Procedure
An agar phantom with a mock-seroma matching patient contours was created and
needles delivered according to the corresponding treatment plan using the developed
system, with needle placement accuracy evaluated using micro-CT.
An agar mock-seroma was created using a 3D printed mould as in Section 2.2.2.1,
with the mould matching CT visible seroma contours, and the above-described agar
mixture without a scattering agent was enriched with 0.5% by mass tungsten powder,
a formula previously validated for speed of sound [31], to provide contrast in CT. Using
a small (5 cm × 4 cm × 4 cm) rectangular container, four 1 cm layers of hyper-echoic and
CT hypo-intense agar were poured and the hypo-echoic, CT hyper-intense mock-seroma
embedded inside. At each layer, four metal ball-bearings 1mm in diameter were placed
at the perimeter of the container, alternating between a box-corners and “+” shaped
pattern, creating 16 CT visible fiducials embedded in a “bounding box” around the
mock-seroma. The bounding box was then embedded inside a phantom breast using a
bowl approximately 12 cm in diameter as a mould. Due to the relatively stiﬀ mechanical
properties of agar, the mould was designed to provide a flat surface at the top of the
breast for imaging. An additional fiducial marker was placed at the outer edge of the
phantom breast to ensure fiducial asymmetry. The phantom breast was then placed on
top of a block of agar 30mm thick with a 10mm deep recess matching the diameter
of the breast phantom to hold the breast phantom stationary. The block and phantom
were then placed on top of a plastic platform designed to fit in the bore of a micro-
CT scanner. An adjustable support for the needle template was also mounted to the
platform and designed to provide 6 DoF’s while keeping metal components separate from
the template.
With the phantom constructed, a micro-CT image (Locus Ultra, General Electric
HealthCare, London, Canada) was captured before and after needle delivery at 120 kVp
and 20mA tube current with isotropic 0.154mm voxels. Prior to implant the mock-
seroma was manually contoured in the pre-treatment micro-CT image at 0.154mm slice
separation. The patient treatment plan, consisting of one fiducial needle and 14 seed-
bearing needles containing 59 seeds, was registered to the pre-treatment micro-CT using a
rigid, surface based registration, the iterative closest point (ICP) algorithm [32], between
the patient and phantom seroma contours, defining the phantom treatment plan.
Three-dimensional US images of the phantom were captured with the developed sys-
tem while stabilized by a counterbalanced mechanical arm and the images manually
contoured. The treatment plan was registered from the pre-treatment micro-CT to the
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Figure 2.7: Screenshot showing visual overlay of planned needle position (purple) and
projected needle trajectory (cyan) on live 2D US image for guidance during needle inser-
tion. Inserted needle is visible in US image beneath purple overlay.
3D US using the ICP algorithm [32] and seroma contours. While the embedded fiducial
markers were visible in 3D US, they were not used to guide the procedure. With the
phantom treatment plan registered to the intraoperative image, the needle template was
registered and its position iteratively adjusted to match the treatment plan. Once the
template position was satisfactory, needles were inserted through the needle template
according to their positions in the treatment plan starting with the fiducial needle and
proceeding from the deepest needles to the most superficial, in keeping with clinical prac-
tice. When inserting each needle, the 2D US transducer was moved by the system such
that the needle was predicted to intersect with the live image and user-initiated adjust-
ments of the transducer position made as necessary. A visual overlay of the desired needle
position was drawn onto the live 2D image (Figure 2.7), providing real-time feedback as
the needle was inserted.
A post-implant micro-CT was obtained with all needles present in the phantom.
Needle positions were manually identified by placing a point at each needle tip and
along each needle shaft. Pre- and post-treatment micro-CT images were registered by
manually placing points at the fiducial beads in each image and performing landmark
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registration. Of the 16 markers near the seroma, 8 were used as fiducials and 8 as targets
to calculate TRE. The 17th asymmetrically placed marker was used only qualitatively to
prevent a ’flipped’ registration due to the otherwise symmetric arrangement of fiducial
markers. In order to quantify FLE, point placement was repeated five times each for the
fiducial needle and half (7) of the mock seed-bearing needles as well as for half (8) of the
embedded markers in both pre- and post-operative images.
Based on registration between the pre- and post-operative micro-CT images, needle
placement error was quantified with respect to tip position and needle trajectory as the
diﬀerence between observed needle positions and the phantom treatment plan. Addi-
tionally, seed positions were extrapolated based on needle positions and the planned seed
configuration within the needles to calculate modelled seed placement error assuming no
additional error due to dropping seeds.
2.2.2.8 Statistical Methods
Linear distances between strings were tested for normality in each direction and depth
setting based on a D’Agostino-Pearson test, using a Bonferroni correction to adjust for
multiple (18) tests. Once the data passed (failed) the tests for normality, 95% confidence
intervals of the mean (median) measurements were calculated using the one sample Stu-
dent’s t-test (Wilcoxon signed rank test) in GraphPad Prism 7 (GraphPad Software, La
Jolla, USA). Ninety-five percent confidence intervals of the diﬀerences in seroma phantom
volume between segmentation and water-displacement measurements were calculated us-
ing a Welch’s t-test. The Welch’s t-test was chosen over a Student’s t-test due to the
dissimilar methods of measurement between groups, suggesting their variances may be
unequal.
TRE following tracking arm validation with and without encoder maps applied was
compared using a paired Student’s t-test using MATLAB 2016a (MathWorks, Natick,
USA). For both tracking arm point accuracy and needle insertion accuracy validation,
95% confidence intervals on the mean error in each axis were calculated using a one-
sample Student’s t-test using MATLAB 2016a (MathWorks, Natick, USA) and a 95%
prediction ellipsoid, an ellipsoidal volume centred on the sample mean such that any
future observation is expected to have a 95% probability of falling within the ellipsoid,
was calculated using principle component analysis.
2.3 Results
2.3.1 Three-Dimensional Image Reconstruction
Of the 18 sets of linear distance measurements, 4 failed the Bonferroni corrected tests
of normality (p<0.05/18). Median values across all directions and depth settings were
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Figure 2.8: Results of linear measurement validation using a 3D grid phantom immersed
in 7.25% by volume isopropyl alcohol solution. Columns and error bars show medians
and 95% confidence intervals, respectively. N=40 per direction, per depth setting.
Table 2.1: Results of volumetric validation comparing segmented volume in 3D US to
water displacement volume. 95% confidence intervals calculated using a Welch ’s t-test.
3D US (cm3) Water Displacement (cm3) Diﬀerence (cm3)
Phantom Mean St. Dev. Mean St. Dev. Mean 95% CI
Seroma 1 5.73 0.04 5.57 0.14 0.16 [-0.06, 0.37]
Seroma 2 3.75 0.03 3.61 0.13 0.15 [-0.08, 0.37]
within ±1.1% (0.11mm) of nominal and 95% confidence intervals of the median were
within ±2.0% (0.20mm), as shown in Figure 2.8.
Volumetric measurements of the seroma-shaped phantoms showed mean segmentation
volumes 2.8% greater than water displacement for the smaller seroma (3.75 ± 0.03 cm3 vs
3.61 ± 0.13 cm3) and 4.1% greater for the larger seroma (5.73 ± 0.04 cm3 vs 5.57 ± 0.14 cm3)
(Table 2.1). Neither diﬀerence was found to be statistically significant (both p = 0.06).
Breast 3D US images captured from a healthy volunteer (Figure 2.9) showed image
quality comparable to clinically used 2D US images, as assessed by the ultrasonographer
who captured them. Images showed no evidence of artefacts due to excessive scanner or
tissue motion and there was little to no evidence of shadowing artefacts due to inadequate
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Figure 2.9: Multi-planar views of a 3D US image captured from a healthy volunteer using
developed system. Left: View showing representative slices of image along orthogonal
planes. Arrows and labels indicate principal axes. Right: View illustrating geometry
of reconstructed scans. Field of view visible in axial-elevational plane is constant across
lateral axis.
coupling at either surface of the TPX™ plate.
2.3.2 Encoder Mapping
Encoder error mapping was performed for the entire range of motion of all three
encoders and the resulting error maps shown in Figure 2.10. Mean angular spacing
between measurement points was 1.1° (SD 0.13°).
Adjacent mounting positions across all encoders had a minimum overlap region of
182 encoder counts (nominally 16°) and, after alignment, had a residual RMSE of <0.06°
(nominally 0.7 encoder counts). In the plotted error maps (Figure 2.10), positive (negat-
ive) slopes in the integral error indicate an over- (under-) estimation of the angle between
two positions, while the first position within the encoder’s range of motion is arbitrarily
chosen as the point from which the integral begins.
2.3.3 Tracking Arm Point Accuracy
Optimization of the zero-points of the encoders yielded oﬀsets within 10 encoder
counts (nominally, 0.88°) of the manually estimated values. RMSE over the range of oﬀ-
sets searched showed a smooth, convex surface with a single global minimum of 0.47mm,
corresponding to an FRE of 0.47mm. With the optimized oﬀsets and registration chosen,
TRE of the remaining validation points was 0.43mm (SD 0.19mm), with a histogram of
the magnitude of target errors shown in Figure 2.11.
The above process of registration and accuracy validation was conducted using the
encoder maps described in Figure 2.10. When repeated with the naïve encoder interpreta-
tion, TRE (FRE) worsened, from 0.43 ± 0.19mm (0.43 ± 0.18mm) to 0.57 ± 0.29mm(0.59 ± 0.26mm).
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Figure 2.10: Integral error of each encoder in the tracking arm as a function of absolute
position when calibrated. Each encoder was calibrated using multiple mounting positions
in order to span the full range of motion. Dashed black line indicates the estimated
integral encoder error after smoothing. All plots show integral error over 360° range
(0–4095 encoder counts).
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Figure 2.11: Normalized histogram of target registration error (TRE) observed during
tracking arm validation plotted with respect to probability (N=240). Dashed black line
indicates mean TRE (0.43 mm).
TRE using the corrected and naïve encoder interpretations were statistically significantly
diﬀerent (p<0.05).
To evaluate directional trends in the observed errors, 95% confidence intervals of the
mean error in each axis were calculated in the arm CS and all intervals found to be
within ±0.07mm as shown in Table 2.2. While two of the three axes (X and Z) were
statistically significantly diﬀerent (p<0.05), the small magnitude of the diﬀerences (<0.05
mm) suggest the biases are not clinically relevant.
The 95% prediction ellipsoid of the validation error, shown in Figure 2.12, has its
Table 2.2: Confidence intervals on the mean error in each axis following tracking arm
point accuracy validation. Error evaluated in the arm coordinate system (Figure 2.2b).
Error (mm)
Axis Mean 95% CI
X (Perpendicular to base of arm) -0.03 [-0.05, 0.00]
Y (Left/Right with respect to base of arm) -0.01 [-0.03, 0.06]
Z (Up/Down with respect to base of arm) 0.04 [0.00, 0.07]
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Figure 2.12: 95% prediction ellipsoid of arm validation error plotted with respect to the
arm coordinate system (units: mm). Black dots indicate individual point measurement
errors and red lines indicate boundaries of 95% confidence ellipsoids. Gray dots and
adjacent ellipses indicate projections of the above onto canonical planes. See Figure 2.2b
for coordinate system description.
direction of largest variance close to the Y axis (angle between 27°), with a 95% prediction
interval along that direction of ±1.0mm.
2.3.4 Image to Scanner Registration
Across all depth settings studied, 3D line models used a mean of 17 points per
string (range: 8–21) and resulted in TRE of ≤0.87mm across all depth settings (FRE
≤0.37mm). TRE and FRE for each depth setting are shown in Table 2.3.
As discussed in Section 2.2.1.2, the scanner and image CSs are nearly coincident.
Translations in the X and Y axis of the scanner CS (Figure 2.2b) were <0.2mm in
magnitude for all depth settings but had a positive translation of 1.8–2.4mm in the Z
axis, the elevational axis of the scan. Similarly, rotation angles in the Y and Z axes were
<0.6°. However, the X-axis, which is parallel with the rotation axis of the tilting portion
of the US transducer’s hybrid motion, had a positive rotation of 1.4–2.4°.
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Table 2.3: Target and fiducial registration error (TRE and FRE) of registering the
scanner and image coordinate systems using a phantom with 12 string intersections (6 fi-
ducials, 6 targets).
Depth Setting (cm) TRE (mm) FRE (mm)
4.0 0.65 0.26
4.5 0.70 0.26
5.0 0.49 0.19
6.0 0.57 0.21
7.0 0.87 0.37
8.0 0.62 0.25
Table 2.4: Mean (SD) of components of template localization errors. Rotations and
translations expressed with respect to the scanner coordinate system (Figure 2.2b). Pos-
itive angles indicate clock-wise rotation about an axis when viewed from the origin.
Rotation Angles (°) Translational Components (mm)
X Y Z X Y Z
0.6 (<0.1) 0.0 (0.1) 1.0 (<0.1) -0.50 (0.06) 1.25 (0.11) 0.66 (0.10)
2.3.5 Template Localization Accuracy
Measurements of individual fiducials on the template showed strong reproducibility,
with a mean deviation distance between repeated measurements of 0.13mm (maximum
0.37mm). However, the mean distance between measured and ground truth locations
for each point was 1.56mm (range 1.17–1.82mm). With respect to the accuracy of the
overall template registration, error transforms as defined in Equation 2.1 showed mean
rotation angles in each axis of <1° (Table 2.4). Translational components were ≤1.25mm
in each axis with the largest transformation in the Y axis, indicating that the template
was measured to be lower (further from the scanner) than expected.
2.3.6 Needle Insertion Accuracy
Mean (± SD) needle tip error across all depth settings was 2.46 ± 0.88mm, with
errors at each insertion depth shown in Table 2.5. At the smallest insertion depth tested
(11 cm), template positions were limited by an inability to submerge the tracking arm
encoders, a constraint not relevant to patient procedures. As a result, only 6–8mm of the
needles at this insertion depth were visible in the 3D US image compared with >20mm
for all other depths, making needle trajectories more susceptible to localization error and
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Table 2.5: Magnitude of needle tip and trajectory error when comparing expected needle
position from tracking and insertion depth to observed needle position in 3D US.
Needle Insertion
Depth (cm)
Magnitude of Needle Tip
Error (mean ± SD) (mm)
Magnitude of Needle Trajectory
Error (mean ± SD) (degrees)
11 2.16 ± 0.46 3.1 ± 2.3a
13 1.60 ± 0.74 1.2 ± 1.0
15 3.15 ± 0.71 1.1 ± 0.3
17 2.92 ± 0.64 0.8 ± 0.4
All 2.46 ± 0.87 1.6 ± 1.5a
All (Excluding
11 cm)
- 1.0 ± 0.6
aVisible length of needle at 11 cm insertion depth was short (≤8mm), leading to increased
error in measuring trajectory. As a result, mean trajectory error is also reported with
this depth excluded.
resulting in a mean trajectory error of 3.1 ± 2.3° compared to means of ≤1.2° for all other
depths. For this reason, trajectory errors are also reported with this insertion depth
excluded, yielding a mean trajectory error of 1.0 ± 0.6°. FLE of the needle tips in 3D US
was found to be 0.26mm.
As in Section 2.3.3, directional trends in the observed errors were assessed using
95% confidence intervals on the error in each axis and by calculating 95% prediction
ellipsoids (Figure 2.13). Statistically significant biases were found in all three axes of
the image CS, with the largest biases approximately 1.5mm in both the elevational and
axial directions. In the axial direction, there was a bias of −1.44mm, indicating that the
needle appears in imaging to be closer to the scanner than expected. This upward bias
may result from a combination of a stronger visibility of the top surface of the needle in
the 3D US image and relatively large blurring eﬀect as a result of the sharp boundary
between the needle and surrounding fluid. Additionally, there was a bias of +1.50mm in
the elevational direction, indicating that the needle tip appeared closer to the scanner’s
motor housing than predicted. The bias in the lateral axis, approximately corresponding
with the needle insertion direction, was smaller at +0.51mm, indicating that the needle
tip appeared further from the needle template than expected.
The 95% prediction ellipsoid of the needle insertion error shown in Figure 2.13, has
its direction of largest variance close to the elevational axis (angle between 23°). The
size of the 95% prediction ellipsoid along this direction is ±3.52mm.
2.3. Results 61
Table 2.6: Confidence intervals on the mean error in each axis following needle insertion
accuracy validation. Error evaluated in the imaging coordinate system (Figure 2.2b) and
averaged across all needle insertion depths.
Error (mm)
Axis Mean 95% CI
Lateral 0.51 [0.26, 0.77]
Axial -1.44 [-1.80, -1.08]
Elevational 1.5 [0.95, 2.06]
Figure 2.13: Ninety-five percent prediction ellipsoid of needle placement error plotted
with respect to the image coordinate system. Black dots indicate individual point meas-
urement errors and red lines indicate boundaries of 95% confidence ellipsoids. Gray dots
and adjacent red ellipsoids indicate projections of the above onto canonical planes. See
Figure 2.2b for coordinate system description.
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Figure 2.14: Post-operative images of phantom procedure. a) Visualization of planned
and observed needle positions overlaid on post-op micro-CT. Planned seed-bearing (fi-
ducial) needles shown in blue (cyan) with observed needles shown in red (pink). Pre-op
seroma following registeration to post-op micro-CT shown in green. b) Reconstucted
plane of 3D US with seroma and all 15 needles visible.
2.3.7 Phantom Procedure
Mean (± SD) needle tip and trajectory error was found to be 2.08 ± 0.73mm and
2.6 ± 0.3°, respectively, with planned and observed positions visualized in Figure 2.14.
Needles in the post-op micro-CT appeared straight, with no signs of bending. Modelled
seed positions showed mean (± SD) seed error of 2.50 ± 0.67mm with a maximum error
of 3.67mm. TRE (FRE) between pre- and post-op micro-CT images was found to be
0.18mm (0.18mm), while FLE for implanted markers and needle tips was 0.06mm and
0.15mm, respectively.
Errors in observed needle tips and trajectories showed a systematic shift. In the
planned template CS, needle tip errors had statistically significant biases of 1.84mm to
the left (+Y, template CS) and 0.38mm down (-Z, template CS). Similarly, the azimuth
and elevation angles of observed needle trajectory errors were both significantly diﬀerent
from 0, with a mean orientation error of 1.5° azimuth (towards template left) and 2.1°
elevation (towards template up).
2.4 Discussion
2.4.1 Three-Dimensional Image Reconstruction
Median linear measurement errors were within ±1.1%, comparable to the 0.1–3.0%
observed in previous 3D US systems [16, 33, 34], while absolute volume diﬀerences of
0.15–0.16 cm3 were comparable or better. However, the relative volume diﬀerence of
2.8–4.1% was higher than those observed in similar systems, likely due to the small
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volumes measured (4–6 cm3 vs 1–288 cm3). Positive feedback on volunteer image quality
indicated acceptable ultrasound coupling between the TPX™ plate and breast while
mitigating motion artifacts.
2.4.2 Encoder Mapping
Encoder error mapping significantly improved the tracking arm’s point accuracy by
25% (0.43mm vs 0.57mm). Overlapping regions of calibration from neighboring mount-
ing positions showed consistent slopes and resulting RMSE of overlapping errors was
within noise-level (nominally 0.7 encoder counts), suggesting that a portion of the encoder
error observed was repeatable and the methodology of empirically aligning neighboring
regions is sound.
2.4.3 Tracking Arm Point Accuracy
Tracking arm point error of 0.43mm is comparable with errors of optical and elec-
tromagnetic (EM) systems, while mitigating their environmental susceptibilities, namely
line of sight obstruction and magnetic field distortion, respectively. A recent review of
EM tracking in medicine described errors of 0.25–1.19mm and 0.26–7.59mm in undis-
torted and distorted environments, respectively [35], suggesting presently reported errors
are comparable to EM tracking in the undistorted case and potentially superior in the
distorted case. Optical tracking has been shown to be accurate to within 0.25–0.35mm
[36], only marginally better than present values. While the mechanical approach presen-
ted is still susceptible to obstructions in its “line-of-reach,” its proximity to the needle
template (≤16 cm) mitigates the burden of this constraint. Although the mechanical
tracking arm is limited to intermittent measurements of unmoving tools in a relatively
small tracking volume, these limitations are thought to be an acceptable compromise for
improved simplicity, cost and environmental sensitivity when localizing a single tool that
remains fixed the majority of the procedure.
In addition to error magnitude, biases present are negligible for the purposes of bra-
chytherapy guidance. Ninety-five percent confidence intervals of the mean error in each
axis are within ±0.1mm. The statistically significant diﬀerences in X and Z (arm CS,
Figure 2.2b) of 0.03mm and 0.04mm, respectively, are of little practical consequence.
With respect to directionality, the largest direction of error (long axis of the 95% pre-
diction ellipsoid, (2.12) was close to the Y-axis of the arm (Figure 2.2b). The eﬀect of
angular uncertainty at a given position is proportional to the distance between the joint
axis and the tip of the arm, causing angular error at the first joint to have the largest
eﬀect on joint position. When the first joint is centred, the derivative of tip position with
respect to the first joint angle is along the Y axis, possibly explaining the large error
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close to that axis.
2.4.4 Image to Scanner Registration
During registration of the 3D US image to the scanner, TRE was <1mm for all depth
settings, with no clear trends at changing depth. The nylon strings created blurring
artifacts of a size not seen in phantom/patient images and the resulting visualization
uncertainties likely account for much of the observed error.
The observed rotation about the lateral axis and translation in the elevational axis
are consistent with image shift due to mechanical backlash in the hybrid motion of the
3D scan. Backlash in the gears of the scanner’s drive-train create a small dead-space
when the transducer motion changes directions, rotating the image about the tilt axis of
the hybrid geometry and bringing the 3D image towards the scanner’s motor housing.
2.4.5 Template Localization Accuracy
Registration of the template to the scanner was achieved with angular errors of <1°
and translational errors of ≤1.25mm. The observed bias in the Y axis, causing the
template to appear 1.25mm lower than expected, was consistent with the bias observed in
Section 2.3.6, with needles appearing 1.5mm higher than expected, potentially indicating
error in the registration of the tracking arm to the scanner. During registration of the
tracking arm to the scanner (Section 2.2.2.3), both calibration and validation of point
measurement accuracy were performed on the same jig, potentially leading to unnoticed
errors in the position of the scanner relative to the jig. However, other sources of error
when evaluating needle insertion accuracy and the use of a single template position in
the template localization accuracy suggest further investigation may be warranted.
2.4.6 Needle Insertion Accuracy
The average (±SD) needle tip error was 2.46 ± 0.87mm, within the dosimetric bench-
mark of 5mm for the smallest 103Pd seed error that would significantly aﬀect dose dis-
tribution [37]. The axes of largest variance and bias, respectively, were both near or
along the elevational axis which, as the reconstructed axis, had the worst resolution.
The elevational axis was also the axis along which the 3D image most deviated from its
expected position, as discussed in Section 2.4.4. Additionally, although 20 needles were
assessed, they represented only four needle template registrations, for which template
registration error will be the same. As a result, directional biases may be exaggerated
by the compromised independence of multiple needle observations taken from the same
template registrations.
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2.4.7 Phantom Procedure
The needles of a PBSI patient treatment plan were successfully delivered to a phantom
with mean (± SD) seed error of 2.50 ± 0.67mm and a maximum error of 3.67mm, meeting
established dosimetric benchmarks (<5mm) [37]. Although the magnitude of the errors
observed was acceptable, a systematic shift was observed. The systematic errors in
needle positioning were likely a result of positioning error at the needle template that is
propagated to all needles.
Mean needle tip error remained similar to needle insertion accuracy (Section 2.3.6;
2.46mm vs 2.08mm) while phantom trajectory error more than doubled (1.0° vs 2.6°).
The increased trajectory error is thought to be due to errors in manually positioning
the orientation of the template. The adjustable template support was designed to fit
inside the micro-CT bore. As a result, rotational DoF’s have their axis of rotation at a
distance of 5–10 cm from their parallel axes in the template CS, creating a levered eﬀect
that made fine rotations difficult. These constraints would not be present during patient
procedures, making a more easily adjusted template support feasible. The presented
phantom procedure used an “open-loop” approach to position the needle template, relying
only on information provided by the tracking sub-system. Alternatively, a “closed-loop”
approach could be adopted using feedback from the first inserted needle to refine the
needle template position and re-insert if necessary, potentially reducing needle placement
error further.
A limitation of this phantom study was that seed positions were extrapolated from
needle positions assuming no additional error due to seed deposition. While errors due
to seed dropping have not been explicitly evaluated in the context of PBSI, needle drag
in permanent seed prostate brachytherapy has been partially implicated as a source of
a systematic bias across patients. A study of seed placement error by Morton et al.
reported no analog to that bias for PBSI procedures [8].
The results of this study should be interpreted in the context of a phantom with
limitations to its fidelity, such as diﬀering mechanical properties, lack of breathing motion
and lack of pre- to intra-operative seroma shift or deformation that may occur in clinical
implants. In particular, rigid registration between manual segmentations of the pre-
and intra-operative seroma would likely be inadequate in a clinical context, suggesting
development of semi-automatic segmentation and deformable registration techniques are
warranted. Additionally, modelled seed error represents an optimistic estimate of implant
accuracy, potentially subject to additional displacements from the seed dropping process.
To our knowledge, this is the first report of a patient or phantom PBSI procedure
guided with intraprocedural 3D imaging. Three-dimensional visualization of the seroma
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intraprocedurally combined with needle template registration is hypothesized to decrease
uncertainty in PBSI guidance and may result in improved seed placement accuracy and
reduced operator dependence of the procedure. Historical experience with high dose-
rate breast brachytherapy techniques suggests operator dependence will be an important
factor in adoption of this procedure, having previously impeded the adoption of intersti-
tial approaches [38] while catapulting the development and adoption of less demanding
intracavitary techniques [4]. Future work includes refinement of the system for improved
template tracking accuracy, non-interventional patient use to collect data for segmenta-
tion and registration development, and a comparison with current practice in phantoms.
2.5 Conclusions
A 3D US guidance system for PBSI has been developed with suitable benchtop per-
formance and image quality in volunteer scans. An integrated template tracking arm
showed point measurement error of 0.43 ± 0.19mm and, in combination with a trackable
template, allowed for tip position and trajectory to be predicted to within 2.46 ± 0.88mm
and 1.6 ± 1.5°. A phantom PBSI procedure was successfully delivered using the system,
to our knowledge the first delivered using intraprocedural 3D imaging, with a mean and
maximum modelled seed error of 2.50 ± 0.67mm and 3.67mm, respectively. Translation
into the clinic is forthcoming, with the ultimate goal of increasing access to BCT by
making PBSI easier for physicians to adopt.
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Chapter 3
Conclusions and Future Work
3.1 Overview and Research Questions
This thesis sought to reduce the operator dependence and procedural complexity of
PBSI by developing a system for intraoperative 3D image guidance tailored to the needs
of the procedure. As clinical data on the efficacy of PBSI matures and its advantages are
recognized, the development of this guidance system is crucial in making PBSI easier for
centres to adopt and ensuring that this promising procedure is available to the women
who would benefit from it.
3.2 Summary and Conclusions
As discussed in Chapter 2, a 3D US system with integrated template tracking has
been developed and its performance systematically validated. Three-dimensional image
reconstruction was shown to have linear and volumetric measurement accuracy consist-
ent with previously reported 3D US systems, and a pilot study with a healthy volunteer
demonstrated its ability to produce high quality images of breast tissue. The developed
tracking arm showed point measurement error of 0.43 ± 0.19mm and allowed the tip pos-
ition and trajectory of inserted needles to be predicted to within errors of 2.46 ± 0.88mm
and 1.6 ± 1.5°. Lastly, a proof-of-concept phantom procedure was performed using the
system that resulted in an average needle tip and trajectory error of 2.08 ± 0.73mm and
2.64 ± 0.28°. Modelled seed positions of the phantom procedure, representing an optim-
istic estimate of implant accuracy, were an average of 2.50 ± 0.67mm from their intended
positions. To our knowledge, this represents the first report of a phantom PBSI procedure
delivered using intraoperative 3D image guidance.
In summary, this thesis describes 1) the design of a novel 3D US guidance system
for PBSI, 2) the systematic validation of the system and characterization of step-wise
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errors in the system, and 3) a proof of concept phantom study illustrating the potential
workflow for adoption of the system in the clinic.
In addition to the development and validation described above, a second system has
been delivered to clinical collaborators in Kelowna, Canada. The system has received
investigational testing authorization by Health Canada for use in scanning patients post-
lumpectomy as part of a feasibility study.
Relative to prior eﬀorts to improve the workflow of PBSI, the developed system is, to
our knowledge, the first to provide 3D image guidance in a common coordinate system
with the delivered needles. An intraoperative coordinate system was first introduced to
PBSI with the template and fiducial needle approach of Pignol et al. in place of a free
hand approach [1]. While the use of a gridded template introduced an intraoperative co-
ordinate system to the procedure, unlike the presently developed system, intraoperative
imaging was not registered to that coordinate system. The spatial relationship between
intraoperative imaging and the needle template could only be approximated by fiducial
needle visibility and visual inspection of the template and US probe. The introduction of
a room-laser and skin tattoos by Batchelar et al. improved on the alignment procedure of
Pignol et al. to make intraoperative set-up and needle template positioning more repeat-
able [2]. However, the use of external tattoos relies on the shifts in external anatomy as a
heuristic for movement of the internal anatomy, where-as the presently developed system
oﬀers the possibility for internal anatomy to be localized directly. Lastly, prior work by
Ravi et al. developing a gamma camera system oﬀered the potential for intraoperative
localization of implanted seeds in 3D [3, 4]. The use of a gamma camera intraoperatively
with PBSI has the advantage of imaging seeds with better contrast than can be achieved
using US due to the radioactivity present in the seeds and absent elsewhere. Additionally,
while the presently described 3D US system guides needle placement, implant quality is
determined by the seed positions. Any additional displacements resulting from the pro-
cess of seed dropping is not reduced by the 3D US system and it remains to be seen
if seeds in breast tissue can be accurately localized using the system. Conversely, the
developed gamma camera system was able to locate seeds in a phantom with a median
error of 1mm [4]. However, unlike the gamma camera system, our 3D US approach can
provide prospective guidance in the delivery of needles to the breast rather than being
limited to assessment of seeds already implanted. Additionally, the gamma camera is
unable to visualize anatomy, and detection of misplaced seeds using the gamma camera
system would require fusing the images it produces with an anatomical imaging modality
such as ultrasound [4]. In this respect, the presented 3D US guidance system has the
distinct advantage of oﬀering a clear value-add to the PBSI procedure as-is, irrespective
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of any further technical developments or incorporation of other technology, where-as the
clinical utility of a gamma camera that is not anatomically aligned is less clear. The
potential advantages oﬀered by the use of a gamma camera may be realized by combin-
ing it with our 3D US system, however clinical translation of our system is warranted
regardless of whether or not the gamma camera system is incorporated.
In addition to placing the present work in the context of previous developments in
streamlining PBSI, an interpretation of the system’s performance with respect to al-
ternative strategies that could have been adopted is warranted. Electromagnetic (EM)
tracking has been previously used for brachytherapy guidance [5–8], as discussed in Sec-
tion 2.4.3 and has the advantage of not requiring line-of-sight. However, the observed
point measurement error of 0.43 ± 0.19mm in the tracking arm was similar to or better
than reported errors for EM tracking; 0.25–1.19mm and 0.26–7.59mm in undistorted and
distorted environments, respectively [9]. While EM tracking oﬀers the potential to track
needles directly, this approach is complicated by the use of pre-loaded needles, with the
seeds to be deposited occupying the usual placement position of EM sensors. As a res-
ult, as discussed in Section 2.2.1, using EM approaches to track needles directly without
altering the clinical workflow would require sensors placed distal to the needle tip and
on every needle, reducing accuracy and drastically increasing the number of sensors re-
quired. Conversely, using an EM approach to track one or both of the needle template or
US transducer would be potentially feasible, subject to modification of the surrounding
equipment to mitigate electromagnetic distortion, such as material selection in the needle
template, template support and patient bed, and the use of a tracked-freehand approach
to 3D US rather than a mechatronic approach. However, the added cost and complex-
ity of an EM system and the requirement of specialized equipment that mitigates EM
distortion are both at odds with the goal of making PBSI easier for clinicians to adopt.
Rather than EM tracking, intraoperative MRI guidance could also have been ex-
plored, having been previously used to guide gynecological [10, 11] and prostate [12]
brachytherapy. However, the spread of these approaches has been limited by access to
MRI and the costs of imaging [13], potentially making the use of MRI an impediment to
adoption rather than an advantage.
Lastly with respect to alternative guidance approaches is the use of optical tracking,
arguably the de-facto standard for medical tool tracking [14]. As discussed in Section
2.4.3, manufacturer reported values for optical tracking point error of 0.25–0.35mm [15]
are marginally better than the presently reported values of 0.43 ± 0.19mm. Additionally,
while optical tracking requires line-of-sight to the tool being tracked, the 3D US scanner
and needle template remain fixed throughout the majority of the procedure, making it
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possible for the line-of-sight requirement to be satisfied only intermittently under the
assumption that the scanner and template remain stationary when tracking is occluded.
The use of optical tracking has the additional advantage of providing continuous rather
than intermittent template tracking, which may be advantageous when adjusting the
template position at the beginning of the procedure. Given these potential advantages
of optical tracking, the selection and development of a mechanical tracking approach
represents a design choice that emphasises simplicity of design and workflow integration.
Introduction of an optical tracking system adds additional equipment to the operating
room, both a camera and a floor or ceiling mount to support it, and the necessary reflect-
ive markers for optical tracking add additional bulk to the scanner and needle template.
Conversely, when not in use, the tracking arm described in this thesis folds against the 3D
US scanner, occupying a space of only 8 cm × 9 cm × 6 cm. For comparison, the smaller of
the two optical tracking systems oﬀered by NDI Medical (Polaris Vicra) is approximately
9 cm × 9 cm × 27 cm in size [15]. Additionally, modifications to the template to allow for
mechanical tracking are limited to unobtrusive and sterilisable divots around the outer
edge rather than potentially bulky, single-use extensions. The complications of intermit-
tent rather than continuous tracking is thought to be surmountable by improvements in
the ability to accurately implement changes to the needle template position using simple
mechanical actuators (e.g. translation stages) incorporated in the needle template sup-
port, discussed further below. Furthermore, the mechanical approach is hypothesized
to be less expensive than an optical or EM tracking approach. While the cost of a
commercially developed tracking arm is difficult to estimate accurately, material costs
at the prototype phase are in the hundreds of Canadian dollars. In comparison, both
optical and EM tracking systems typically cost tens of thousands of dollars. The ability
to implement controlled, mechanically actuated adjustments would allow for template
position changes to be made accurately and precisely, mitigating the need for continuous
feedback. The resulting system is thought to be better suited for smooth integration
into the operating room, a key consideration for a project aimed primarily at facilitating
adoption.
3.3 Limitations
The largest limitation of the presented work is that much of the utility of the de-
veloped system rests on the underlying presumption that its use will make PBSI easier
for clinicians to learn and repeatably deliver. As was described in Chapter 1, the ulti-
mate goal of developing the presented system is to facilitate the adoption of PBSI by
simplifying and streamlining the procedure through the use of an intraoperative guidance
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system. The presented investigation explores only the calibration and accuracy of the
guidance system, and while accuracy is a necessary condition for the system’s intended
impact, it is not a sufficient condition. While the application of image guidance tools in
other areas of brachytherapy, particularly permanent seed prostate implants, and input
from the PBSI team in Kelowna, Canada provide support for the presumed impact of the
system, the eﬀect of its use in the clinic remains to be seen. Validating the expected im-
pact of the developed guidance system on the clinical workflow and operator dependence
of PBSI will be a key focus of future work, discussed further below.
With respect to the system itself, the guidance oﬀered by the developed system centres
primarily on the guidance of needles to their intended location, but the dosimetric quality
of the implant is determined by the position of the implanted seeds. The introduction
of any additional displacements between the “modelled” seed position, as described in
the phantom procedure of Chapter 2, and the final implanted locations of the seeds are
not expected to be reduced by using the developed system. Additionally, post-implant
migration of the seeds has been observed and also contributes to implant quality [16],
but is unlikely to be aﬀected by the system’s use. Lastly, while the proof-of-concept
phantom procedure used a rigid, surface based registration to align the pre-operative
plan with intraoperative imaging, seroma deformations and diﬀerences in appearance
between CT and 3D US would make this approach inadequate for patient procedures.
As a result, the presently used process of using skin tattoos and other external markers
for intraoperative patient setup would likely still be required to supplement the guidance
provided by 3D US imaging until future work integrating (semi-) automatic segmentation
in 3D US and non-rigid registration with CT, discussed further below, can be developed
and incorporated.
3.4 Future Work
A number of additional areas of research remain to be explored in the application of
this device, including further refining the device’s hardware and software as well as work
related to its clinical translation.
3.4.1 Device Refinements
3.4.1.1 Hardware Refinements
The work described in Chapter 2 identified the measurements made by the template
tracking arm and its registration to the 3D US scanner as a dominant source of residual
guidance error. To this end, future work in refining the physical construction of the
tracking arm and its method of registration to the 3D US scanner is warranted for future
iterations of the device. With respect to the tracking arm, it was observed during testing
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that the tracking arm was susceptible to small amounts of bending in the lengths of the
arm during use. For instance, with the scanner and arm held in fixed positions, a modest
amount of force on the most distal joint of the arm (e.g. pushing on the joint with my
pinky finger) could result in a change in the measured arm position of up to 1.4mm.
This error is large enough to potentially explain the discrepancy observed in Chapter 2
between validation of point measurement error (mean 0.43mm) and the point-wise error
observed during template localization (mean 1.56mm). A susceptibility to deformation
would also present an obstacle to the robustness of the system’s performance in a practical
scenario. To lessen the tracking arm’s susceptibility to bending under force, future work
could consider using stiﬀer materials than the 3D printed nylon used currently or the use
of machined components rather than 3D printed ones. Alternatively, size or shape of the
lengths could also be considered to increase the moment of inertia of the beam in axes
most susceptible to load, such as an I-beam shape in the two most distal joints oriented
parallel with the axis of the joint between them.
Additionally, as was alluded to in Section 2.4.7, the ability of the device’s template
tracking to guide template positioning is limited by the user’s ability to implement de-
sired changes. While the configuration of the template support used during the phantom
procedure made fine rotational adjustments challenging, future work in refining the tem-
plate support used intraoperatively could mitigate these challenges during patient pro-
cedures. The incorporation of calibrated translation and/or rotation stages in the needle
template support would allow a simple and reliable mechanism for adjusting the needle
template based on measurements made using the template tracking arm. The geometry
of the stages, including the axes of translation and centres of rotation with respect to
the template, could be incorporated into the device’s accompanying software so that the
adjustments necessary to move the template to a given position and orientation could be
calculated automatically and displayed for the user to implement. In this way, a closed
loop could be more accurately created between measurements and adjustments of the
template position, expediting needle template setup and enhancing the value added to
the procedure through use of the system’s template tracking.
Furthermore, during registration of the 3D US image to the geometry of the scanner, a
shift in the image consistent with mechanical backlash was observed. This backlash causes
3D images to show a small region at one extent of the volume in which 2D US frames have
been repeated, consistent with measured encoder motion in the ‘dead space’ of the gears
when the 2D US transducer has not yet moved. While the eﬀects of the backlash on image
position are accounted for in the registration process, the consistency in the amount of
backlash in the gears over time remains to be seen, possibly requiring more frequent
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recalibration. Additionally, the backlash phenomenon may also be contributed to by
backlash resulting from physical bending in the links between the motor and transducer,
particularly in the 3D printed plastic components customized to the transducer model
that link it to the rest of the drive-train. Backlash due to deformation may vary with the
contact pressure applied between the scanner and the skin, particularly if the TPX™ plate
bends enough to make contact with the US transducer, which would alter the position of
the 3D image with respect to the scanner, leading to targeting error. For these reasons,
consistency of the relationship between the 3D image and the probe volume over time
and as a function of contact pressure should be explored. It may also be advantageous
to move the position of the encoder further down the drive train to be closer to the
transducer in order to minimize the eﬀect of backlash in the first place.
In addition to improving the accuracy of the system, practical considerations of the
device’s use in a sterile environment should also be considered in future work. Sterility at
the imaging surface will most likely be accomplished by ‘bagging’ the device with a sterile
cover. Conversely, sterility at the interface of the tracking arm and needle template may
be accomplished by either a ‘bagging’ strategy or by using a ‘cheater plate’ that mounts
to the needle template via the existing gridded template holes. The plate would have
the fiducial divots used for registration around its outer edges, allowing the tracking arm
to ‘cheat’ by measuring the position of a sterilisable plate as a proxy for the template
itself. As a result of the non-sterile pre-setup technique developed by Batchelar et al. [2],
the devised solution should accommodate the use of the device both before and after the
surrounding skin is sterilized, such as by allowing a sterile covering to be donned during
the procedure.
3.4.1.2 Software Refinements
With respect to the device’s software and user interaction, future work should focus
on features that aid in the interpretation of the data generated by the guidance system,
including segmentation and registration algorithms. As was alluded to in Section 2.4.7,
the use of a rigid registration between planning CT and intraoperative 3D US seroma
contours would be inadequate for patient cases. As was discussed in Section 1.3.3, the
breast is a highly mobile and deformable organ and the seroma’s appearance in CT and
US is fundamentally diﬀerent due to the underlying bases of image formation in each
modality. Additionally, manual contouring of 3D US images during the procedure would
be impractical. While use of the system in the current clinical workflow for needle tem-
plate positioning would be valuable to clinicians, the utility of the system would be better
leveraged by incorporation of segmentation and registration algorithms to streamline the
workflow using internal landmarks rather than external ones. Future work in this area
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would include the development of an automatic or semi-automatic seroma segmentation
algorithm to be applied to intraoperative 3D US images. Intraoperative seroma segment-
ation would oﬀer improved visualization of the surgical target with respect to the needle
template as well as allow for quantitative feedback on the position of the needle tem-
plate with respect to the seroma, such as quantifying the distance between the expected
trajectory of the fiducial needle and the centroid of the seroma.
Additionally, coupling the seroma segmentation algorithm with a non-rigid registra-
tion to the pre-operative plan would allow for intraoperative visualization of the 3D
treatment plan and intraoperative estimates of dosimetry. Given the modality depend-
ence of the seroma’s size and shape, one possible strategy for achieving this non-rigid
registration would be to use a multi-step approach. The pre-operative CT used for cre-
ation of the treatment plan would be non-rigidly registered to a pre-operative 3D US
image which is in turn registered to the intra-operative 3D US image using a non-rigid,
boundary based approach such as thin plate spline registration. By treating the regis-
tration as a multi-step process, state of the art registration techniques may be used to
tackle the challenging problem of non-rigid, CT to 3D US breast registration with min-
imal concern for computational complexity, simplifying the remainder of the registration
task which must be performed in a time-sensitive context. The addition of a 3D US scan
during treatment planning would be consistent with previous literature suggesting its
value [17].
In addition to software tools assisting with plan registration and needle template
alignment, the incorporation of needle segmentation algorithms could be of additional
assistance in guiding needle insertion once the template is aligned. With previously
developed algorithms for segmentation of multiple needles from a 3D US volume [18]
available and work within the lab on real-time segmentation of a needle in a 2D US
image ongoing, future work in this area would require only adaptation and validation of
techniques developed for other applications.
3.4.2 Clinical Translation
In addition to future work refining the device’s capabilities, clinically oriented future
work is also necessary to move the device towards guiding patient procedures. As was
mentioned above, the device has already been given investigational testing authorization
by Health Canada for imaging of the breast. Irrespective of any further development
or validation, the device is ready to be put to use in a usability study, capturing im-
ages of patients post-lumpectomy during the planning stages of PBSI or other breast
radiotherapy. Future work in this area will allow for early feedback from end users on
80 Chapter 3. Conclusions and Future Work
device usability, user interface and feature requests. Additionally, images generated from
usability testing will provide data to develop and test the proposed segmentation and
registration algorithms described above.
Furthermore, to evaluate the hypothesis that the developed system will improve accur-
acy and operator dependence of the procedure, future work should evaluate the delivery
of a mock-PBSI procedure in a phantom using both the presently described system and
the current clinical techniques and compare the resulting procedure time and seed place-
ment accuracy. Evaluation in a phantom allows for comparisons to be made in delivering
the same plan to the same anatomy, a level of control which would not be possible in
patient populations. These phantom procedures would like ly follow a similar workflow
to the phantom procedure described in Section 2.2.2.7, with the following modifications.
First, the use of a higher fidelity phantom that allows for more accurate modelling of
the mobile and deformable nature of the breast. Movement and non-rigid deformation of
the internal target is a key challenge of the procedure and should be accounted for in a
comparison study. Second, the phantom procedure should be conducted by an operator
more representative of the skill set of a radiation oncologist who might adopt the proced-
ure, such as a radiation oncologist who has not previously performed a PBSI procedure
or a radiation oncology resident. Employment of a user untrained in percutaneous in-
terventions would unfairly favor the guided procedure by inaccurately representing the
clinical judgement available during the 2D US guided approach. Lastly, the phantom
study should employ the deposition of (non-radioactive) seeds into the phantom. The
use of seeds was avoided in the reported phantom procedure because of the potential for
unrepresentative errors to be introduced due to the limited skill set of a non-clinically
trained user. Furthermore, it would not have been possible to diﬀerentiate between error
due to seed-dropping and error due to the guidance system. Employing a more repres-
entative user and comparing the results to a control intervention in which seed-drop error
is also present would avoid those concerns, making a higher fidelity phantom procedure
practical.
Lastly, assuming favourable findings from the phantom comparison study, future work
should include a pilot study in which the device is used to guide PBSI intraoperatively.
To reduce the total number of patients that need to be enrolled in such a study before
a conclusion may be made, a timeseries design could be used, in which metrics such as
procedure time and seed implantation error for patients treated at a given centre are
compared before and after the adoption of the guidance system during the procedure.
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Appendix A: Letter to the Editor
The contents of this appendix have previously been published as a letter to the editor:
Michael J, Crook J, Morton D, Batchelar D, Hilts M, Fenster A. Reply to: Who Should
Bear the Cost of Convenience? A Cost-eﬀectiveness Analysis Comparing External Beam
and Brachytherapy Radiotherapy Techniques for Early Stage Breast Cancer. Clin Oncol.
2017;29(6):392-393. doi:10.1016/j.clon.2017.03.003. Permission to reproduce the article
was granted by Elsevier and is provided in Appendix D.
We read with interest, Who Should Bear the Cost of Convenience? A Cost-eﬀectiveness
Analysis Comparing External Beam and Brachytherapy Radiotherapy Techniques for
Early Stage Breast Cancer [1], and seek to comment on the eﬀect of patient travel dis-
tance on total procedure cost.
The authors modelled patient travel cost using the Canada Revenue Agency (CRA)
travel allowance and a one-way travel distance of 38 km. The reported sensitivity analysis
considered variations of ±50% (19–57 km) and found treatment cost ranking remained
unchanged. However, patient travel distance can greatly exceed 57 km. For instance, at
the Centre for the Southern Interior (CSI) in Kelowna, Canada, patients are drawn from
up to 375 km away.
While the maximum distance investigated did not change treatment cost rankings, is
there a threshold distance that would? The travel cost model’s linear nature and reported
sensitivity analyses allow the reader to infer a threshold of approximately 94km. Above
this threshold, the model appears to predict total costs of PBSI to be lower than WBI.
At the CSI, two of the four regions served lie entirely outside of this 94 km threshold,
representing 25% of patients, while both of the other regions extend partially outside of
it. In total, an estimated 45% of CSI breast cancer patients reside >94 km away.
With respect to the travel cost model, the CRA travel allowance is given “in addition
to salary or wages” [2], suggesting it does not account for the value of patients’ time
during travel. Additionally, no consideration is made for patients requiring overnight
lodging. Both of these considerations suggest the true threshold distance is lower.
While this paper is already a timely and valuable contribution, the consideration of
greater travel distances has important implications for centres serving large geographical
areas. We invite the authors to comment on the threshold distance described using
original data.
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Explanatory Note - Calculations
The calculation of travel costs in “Who Should Bear the Cost of Convenience?”, are
described as follows:
To estimate travel costs, an average one-way travel distance of 38 km was cal-
culated based on the travel distance for patients undergoing cancer treatment
reported by three previous studies [23-25]. This was multiplied by the Canada
Revenue Agency travel allowance for 2013 (0.54 $/km) [26] and summed over
all appointments for each technique.
From this description, it can be inferred that travel cost as calculated for a given treat-
ment method can be described as:
Travel Cost = One Way Travel Distance × 2 × Travel Allowance per km ×
Number o f Appointments
The above equation implies that travel cost is proportional to travel distance, further
implying that each added kilometer to one-way travel distance increases the total cost of
the procedure by a constant amount. The added cost of each kilometer of travel distance
can be inferred from results of the sensitivity analysis according to the equation,
Cost per km Travel Distance =
Total Treatment Cost × % Cost Change in S ensitivity Analysis
Distance Change in S ensitivity Analysis
Applied to each of WBI and PBSI, this equation yields a cost per km for each pro-
cedure of,
Total Treatment
Cost (Base Case)
% Cost Change in
Sensitivity Analysis
Distance Change in
Sensitivity Analysis (km)
Cost
per
km
WBI $ 6,200.00 18% 19 $58.74
PBSI $ 8,700.00 3% 19 $13.74
Diﬀ. $ (2,500.00) - - $45.00
From the above, the travel distance at which the two procedures have equal total cost
(critical distance) may be calculated as follows,
Critical Distance = Base Case Distance +
Total Cost Di f f erence
Di f f erence in Cost per km
= 93.6 km
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Appendix B: 94km Map - Methods
The map of travel distance thresholds around Canadian radiation therapy centres de-
scribed in Chapter 1 was created by:
1. Identifying the locations of Canadian radiation therapy centres,
2. Identifying areas within 93.6 km travel distance from one or more centres,
3. Cropping the identified areas to include only regions in Canada, and
4. Estimating the proportion of the Canadian population outside the identified areas
using NASA’s Gridded Population of the World, Version 4.
Canadian radiation oncology centres were identified using lists of cancer centres pub-
lished by the Canadian Association of Radiation Oncology1 and the Canadian Organiz-
ation of Medical Physicists.2 These lists were supplemented with additional information
from Alberta Health Services.3 GPS coordinates of the manually identified cancer centres
were identified using a custom map in Google My Maps and exported as a KML file. A
complete list of the centres identified is included below.
To identify the areas within 93.6 km of one or more of the identified cancer centres,
custom MATLAB functions were created using MATLAB 2016a (MathWorks, Natick,
USA) to parse the GPS locations of the centres from the exported KML file. 93.6 km
travel-distance isolines were sequentially requested around each location using the MAT-
LAB ‘webread’ function and a trial version of the HERE application programming in-
terface (API).4 The HERE API is a third party service that interfaces with the Google
Maps API and returns requests in JSON format. The returned JSON files contained
GPS coordinates defining the travel-distance isoline for each location which was, in turn,
written to a KML file as separate, possibly overlapping, polygons. The KML file contain-
ing the polygons was then loaded into the open-source geographic information system
(GIS) software QGIS5 which was used to merge (‘dissolve’) the overlapping contours into
non-overlapping ones.
1http://www.caro-acro.ca/patients/canadian-radiation-oncology-centres/
2http://www.comp-ocpm.ca/english/career-education/career-resources/canadian-cancer-
centres.html
3http://www.albertahealthservices.ca/info/service.aspx?id=1025904
4https://developer.here.com/
5http://www.qgis.org/en/site/
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Once merged, an outline of the Canadian border was downloaded from the Database
of Global Administrative Areas (GADM)6 and imported into QGIS. Merged isolines
were cropped to the Canadian border using the ‘clip’ tool and re-saved as a KML file
that was uploaded to Google My Maps. The result, including names and locations of
the cancer centres identified and the merged and cropped isolines, are available here:
http://bit.ly/94kmMap
Lastly, the proportion of the Canadian population outside of the identified regions was
calculated by summing published data of population by area across Canada and across
the regions within the 93.6 km isolines. Population data were taken from the United
States National Aeronautics and Space Administration (NASA) Gridded Population of
the World, Version 4.7 The downloaded population data parcel the geography of the world
into a grid with a resolution of 30 arc-seconds (approximately 1 km at the equator) and
contain an estimate of the population within each cell of that grid. Population data was
cropped to the Canadian border, as defined by the GADM data mentioned previously,
using QGIS and the total population within determined. The above process was then
repeated using the merged and cropped 93.6 km isolines rather than the Canadian border.
The proportion of the Canadian population inside the isolines was calculated as the ratio
of the two population estimates and the proportion outside the isolines taken as its
complement.
Identified Canadian Radiation Oncology Centres
• BC Cancer Agency - Abbotsford Centre, Abbotsford, British Columbia
• BC Cancer Agency - Centre for the North, Prince George, British Columbia
• BC Cancer Agency - Centre for the Southern Interior, Kelowna, British Columbia
• BC Cancer Agency - Fraser Valley, Surrey, British Columbia
• BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia
• BC Cancer Agency - Vancouver Island Centre, Victoria, British Columbia
• Cross Cancer Institute, Edmonton, Alberta
• Tom Baker Cancer Centre, Calgary, Alberta
6http://www.gadm.org/country
7http://sedac.ciesin.columbia.edu/data/collection/gpw-v4
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• Central Alberta Cancer Centre, Red Deer, Alberta
• Jack Ady Cancer Centre, Lethbridge, Alberta
• Allan Blair Cancer Centre, Regina, Saskatchewan
• Saskatoon Cancer Clinic, Saskatoon, Saskatchewan
• Cancer Care Manitoba, Winnipeg, Manitoba
• Cancer Care Manitoba (Brandon), Brandon, Manitoba
• Windsor Regional Cancer Program, Windsor, Ontario
• London Regional Cancer Program, London, Ontario
• Grand River Regional Cancer Centre, Kitchener, Ontario
• Juravinski Cancer Centre, Hamilton, Ontario
• Carlo Fidani Peel Regional Cancer Centre, Mississauga, Ontario
• Odette Cancer Centre, Toronto, Ontario
• Princess Margaret Cancer Centre, Toronto, Ontario
• Stronach Regional Cancer Centre, Newmarket, Ontario
• R.S. McLaughlin Durham Regional Cancer Centre, Oshawa, Ontario
• Cancer Centre of Southeastern Ontario, Kingston, Ontario
• The Ottawa Hospital Cancer Centre, Ottawa, Ontario
• Simcoe Muskoka Regional Cancer Centre, Barrie, Ontario
• North East Cancer Centre, Sudbury, Ontario
• North West Regional Cancer Care, Thunder Bay, Ontario
• McGill University Health Centre, Montreal, Quebec
• Jewish General Hospital, Montreal, Quebec
• Hôpital Maisonneuve-Rosemont, Montreal, Quebec
• CHUM Hôpital Notre-Dame, Montreal, Quebec
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• Hôpital Charles Lemoyne, Greenfield Park, Quebec
• CSSSL - Hôpital de Laval, Laval, Quebec
• CSSSRN - Rimouski, Rimouski, Quebec
• CHRTR - Trois-Rivières, Trois-Rivières, Quebec
• CHUQ - Hôtel-Dieu de Québec, Quebec City, Quebec
• CSSSG - Centre Hospitalier de Gatineau, Gatineau, Quebec
• CHUS - Centre Hospitalier Unviersitaire de Sherbrooke, Sherbrooke, Quebec
• CSSS - Complexe Hospitalier de la Sagamie, Chicoutimi, Quebec
• Dr. Léon-Richard Oncology Centre, Moncton, New Brunswick
• Saint John Regional Hospital, Saint John, New Brunswick
• Nova Scotia Cancer Centre, Halifax, Nova Scotia
• Cape Breton Cancer Centre, Sydney, Nova Scotia
• Dr. H. Bliss Murphy Cancer Clinic, St. John’s, Newfoundland and Labrador
• PEI Cancer Treatment Centre, Charlottetown, Prince Edward Island
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Michael, J; Morton, D; Batchelar, D; Hilts, M; Crook, J; Fenster, A (Jul 2017)
3D Ultrasound Image Guidance for Permanent Seed Breast Brachytherapy: System Development
and Benchtop Validation (10 minutes)
SPIE MEDICAL IMAGING - ORLANDO, FL
Michael, J; Morton, D; Batchelar, D; Hilts, M; Fenster, A (Feb 2017)
Intraoperative 3D Ultrasound Guidance System for Permanent Breast Seed Implantation (20
minutes)
BIOMEDICAL ENGINEERING SEMINAR SERIES - LONDON, ON
Michael, J; Batchelar, D; Fenster, A (Nov 2016)
Development of a Three-Dimensional Ultrasound Scanner and Needle Template Localizing Arm
for Guidance of Permanent Seed Breast Brachytherapy (15 minutes)
INNOVATIONS IN RADIATION ENGINEERED THERAPY - TORONTO, ON
Michael, J; Batchelar, D; Fenster, A (Nov 2016)
Developing a 3D Ultrasound Guidance System for Permanent Breast Seed Implantation (15
minutes)
LONDON IMAGING DISCOVERY DAY - LONDON, ON
Michael, J; Batchelar, D; Fenster, A (Jun 2016)
Development of a Three Dimensional Ultrasound Scanner and Template Localizing Arm for Guid-
ance of Permanent Seed Breast Brachytherapy (10 minutes)
BIOMEDICAL ENGINEERING RESEARCH DAY - LONDON, ON
Michael, J; Batchelar, D; Fenster, A (Apr 2016)
Development & Validation of a Three Dimensional Ultrasound System for Guidance of Permanent
Breast Seed Implantation in the Treatment of Breast Cancer (15 minute talk & poster)
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BIOMEDICAL ENGINEERING SEMINAR SERIES - LONDON, ON
Michael, J; Batchelar, D; Fenster, A (Feb 2016)
Three-Dimensional Ultrasound Guidance of Low Dose Rate Brachytherapy for Breast Cancer (15
minutes)
POSTER PRESENTATIONS
CANADIAN ORGANIZATION OF MEDICAL PHYSICISTS (COMP) ANNUAL SCIENTIFIC
MEETING - OTTAWA, ON
Morton, D; Michael, J; Batchelar, D; Hilts, M; Fenster, A; Crook, J; (Jul 2017)
The Value of 3D Ultrasound in Permanent Breast Seed Implant Brachytherapy
ROBARTS RESEARCH RETREAT - LONDON, ON
Michael, J; Morton, D; Batchelar, D; Hilts, M; Crook, J; Fenster, A (Jun 2017)
3D Ultrasound Image Guidance for Permanent Breast Brachytherapy: System Development and
Benchtop Validation
ONCOLOGY RESEARCH AND EDUCATION DAY - LONDON, ON
Michael, J; Morton, D; Batchelar, D; Hilts, M; Crook, J; Fenster, A (Jun 2017)
3D Ultrasound Image Guidance for Permanent Breast Brachytherapy: System Development and
Benchtop Validation
LONDON HEALTH RESEARCH DAY - LONDON, ON
Michael, J; Morton, D; Batchelar, D; Hilts, M; Fenster, A (Mar 2017)
A Guidance System for Permanent Seed Radiotherapy of the Breast Using 3D Ultrasound and
Mechatronic Template Tracking
ONTARIO INSTITUTE OF CANCER RESEARCH (OICR) SCIENTIFIC MEETING - TORONTO,
ON
Michael, J; Morton, D; Batchelar, D; Hilts, M; Fenster, A (Mar 2017)
Developing Intraoperative Image Guidance of Permanent Seed Breast Brachytherapy
ANNUAL MEETING OF THE IMAGING NETWORK OF ONTARIO - TORONTO, ON
Michael, J; Morton, D; Batchelar, D; Hilts, M; Fenster, A (Mar 2017)
3D Ultrasound and Mechatronic Template Tracking for Guidance of Permanent Seed Breast Bra-
chytherapy
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ONCOLOGY RESEARCH AND EDUCATION DAY - LONDON, ON
Michael, J; Batchelar, D; Fenster, A (Jun 2016)
A Mechanical 3D Ultrasound System for Intraoperative Guidance of Breast Brachytherapy
ROBARTS RESEARCH RETREAT - LONDON, ON
Michael, J; Batchelar, D; Fenster, A (Jun 2016)
A Mechanical 3D Ultrasound System for Intraoperative Guidance of Breast Brachytherapy
ANNUAL MEETING OF THE IMAGING NETWORK OF ONTARIO - TORONTO, ON
Michael, J; Batchelar, D; Fenster, A (Mar 2016)
Development of a Three Dimensional Ultrasound System for Guidance of Permanent Breast Seed
Implantation
LONDON HEALTH RESEARCH DAY - LONDON, ON
Michael, J; Batchelar, D; Fenster, A (Mar 2016)
Developing Three Dimensional Ultrasound Guidance of Permanent Seed Brachytherapy for Breast
Cancer
COMMUNITY INVOLVEMENT
CONFERENCECO-CHAIR | ROBARTS RESEARCH INSTITUTE
October 2016 - June 2017 | London, ON
COMMITTEEMEMBER | ROBARTS ASSOCIATION OF TRAINEES
October 2016 - July 2017 | London, ON
SESSIONVOLUNTEER - LET’S TALKCANCER | CANADIAN CANCER SOCIETY’S
RESEARCH INFORMATION OUTREACH TEAM
May 2016 & May 2017| London, ON
MASTEROFCEREMONIES | UNIVERSITY OF GUELPH ENGINEERING SOCIETY
PROFESSIONAL DEVELOPMENT CONFERENCE
Jan 2015 | Guelph, ON
CONFERENCECHAIR | ENGINEERING STUDENT SOCIETIES’ COUNCIL OF ONTARIO
PRESIDENT’S MEETING
Dec 2013 – Sep 2014 | Guelph, ON
VICE-PRESIDENT EXTERNALAFFAIRS | UNIVERSITY OF GUELPH ENGINEERING
SOCIETY
Apr 2013 – Apr 2014 | Guelph, ON
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ACADEMICCOMMUNITY BUILDER | UNIVERSITY OF GUELPH
Sep 2012 – Sep 2013 | Guelph, ON
“BIG BUDDY” (ENGINEERINGORIENTATIONVOLUNTEER) | UNIVERSITY OF
GUELPH
Sep 2012 – Sep 2013 | Guelph, ON
DIRECTOR – ESSCOCONNECTS | ESSCO
Jun 2012 – Jun 2013 | Guelph, ON
VARSITYATHLETE | UNIVERSITY OF GUELPH VARSITY ROWING TEAM
Sep 2010 – Dec 2012 | Guelph, ON
CLASS REPRESENTATIVE | UNIVERSITY OF GUELPH ENGINEERING SOCIETY
Sep 2010 – Apr 2012 | Guelph, ON
99
